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ABSTRACT 
MOLECULAR CHARACTERIZATION OF THE PATHOPHYSIOLOGY OF THE DIGITAL LAMINAE IN 
ACUTE CARBOHYDRATE-INDUCED EQUINE LAMINITIS 
SEPTEMBER 2013 
 
ERICA A. PAWLAK, B.S., MICHIGAN STATE UNIVERSITY 
 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Professor Samuel J. Black 
 
 
 Equine laminitis is a devastating condition that results in the failure of the tissue 
responsible for suspending the skeleton within the hoof capsule.  The digital laminae is 
composed of two interdigitated layers, the dermal lamellae surrounding the distal pedal bone, 
and the epidermal lamellae, which interfaces with the hoof wall.  During laminitis, these layers 
separate, allowing for rotation and sinking of the pedal bone.  While there are multiple diseases 
and physiological conditions associated with the development of laminitis, including sepsis, 
metabolic syndrome, and unequal weight bearing, the exact cause remains elusive.    Prior work 
by our research group identified the metalloprotease ADAMTS-4 as a potential early instigator 
of disease.  The data presented herein catalogs the distribution of the substrates of this enzyme, 
aggrecan and versican, the ramifications of ADAMTS-4-mediated versican loss in the laminae, 
and further expands into the repression of the canonical wnt signaling pathway and potential 
additional metalloprotease (MMP) involvement in disease, utilizing a model of acute, 
carbohydrate-induced laminitis.  Additionally, samples from other models of laminitis induction 
and clinical samples were screened for differential expression of relevant gene markers, 
including versican, members of the canonical wnt signaling pathway, and MMP-1 and -13.  
Together, these data provide a characterization of laminar pathology in the carbohydrate-
 vii 
induced model, as well as highlighting key similarities and differences amongst multiple 
methods of disease development, and lay important groundwork for developing clinical 
therapeutic interventions.  
 viii 
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CHAPTER 1 
 
INTRODUCTION 
 The equine digital laminae is a complex tissue that is responsible for suspending the 
axial skeleton of the horse within the hoof capsule.  Laminae are composed of 500 to 600 
vertical folds of keratinized epidermal tissue, the primary epidermal laminae, which are 
contiguous with the inner hoof wall, and interdigitated folds of connective tissue, the primary 
dermal laminae, which are contiguous with the distal phalanx (Figure 1.1).  Each of these 
primary projections further contains 150-200 secondary projections, known as the secondary 
epidermal and dermal lamellae, respectively, which increase the surface area of the interface 
between the two tissue types.  These two tissues are separated by a basement membrane 
which lies adjacent to the basal epithelium of the secondary epidermal lamellae1,2.   
 Equine laminitis is a disease that results in the structural failure of the digital laminae.  
Laminitis occurs secondary to a variety of systemic pathological conditions, excess carbohydrate 
consumption, sepsis, metabolic and/or endocrine dysfunction, gastrointestinal injury or 
impaction, unequal weight bearing secondary to an injury to the contralateral limb, and black 
walnut heartwood toxemia3.  The end result of these disease processes is the separation of the 
dermal and epidermal lamellae, which allows for rotation and sinking of the distal phalanx due 
to increased force applied by the digital flexor tendon and the weight borne on the hoof.  In 
severe cases, the bone may actually penetrate the bottom of the hoof.  This condition causes 
crippling lameness which commonly results in humane euthanasia of the animal.  The severity of 
disease is measured by the Obel Scale, with a score of 1 corresponding to lameness only 
discernible at the trot, and a maximum score of 4 corresponding to near total recumbence4. In 
the United States, approximately 2% of the 9.2 million horses are affected by laminitis, 
substantially disrupting the estimated $39 billion domestic equine industry5.  Because of an 
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overall lack of understanding of the underlying pathophysiology of laminitis, the equine patient, 
client, and equine veterinarian have suffered though decades of treatment failures, which has 
led the USDA, the Morris Animal Foundation, and the American Association of Equine 
Practitioners to deem laminitis a research priority. 
 Much of our knowledge on the development of laminitis is the result of studies in model 
induction systems.  The two models used primarily at the start of the studies included in this 
dissertation were carbohydrate overload (CHO), which encompassed dosing a horse with a 
starch gruel (85% corn starch and 15% wood flour suspended in water)6, and the black walnut 
heartwood extract (BWE) model.  BWE-induced laminitis displays rapid onset but is transient 
and will spontaneously resolve.  Laminar inflammation occurs within 2 hours of toxin 
administration, and lameness is first noted by 10-12 hours after treatment, but animals rarely 
develop laminitis past Obel Grade 1 (OG1)7.  In contrast, CHO-induction mimics accidental grain 
ingestion or pasture-associated laminitis, with OG1 lameness occurring at around 24 hours post 
treatment and OG3 lameness occurring at around 40 hours6.  More recently, carbohydrate 
overload induction methods utilizing oligofructose (OF)8, which more accurately mimics the 
carbohydrates found in lush pasture grass, and induction with a prolonged euglycemic-
hyperinsulinemic clamp (p-EHC)9 have been developed.   
Histologic analyses of laminae from horses with experimentally-induced and naturally 
acquired laminitis show several pathologic features that may contribute to their failure.  These 
include increased apoptosis of basal epithelial cells10, reduced presence of hemidesmosomes in 
basal epithelial cells resulting in diminished attachment to the basement membrane, and loss of 
anchoring filaments that attach the basement membrane to adjacent fibrillar collagen2 of the 
secondary dermal laminae.  In addition, sections of laminae from laminitic horses show 
infiltration of the dermal laminae by inflammatory leukocytes11,12.  Determining the enzymes 
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that mediate this damage is an essential step towards identifying therapeutic inhibitors.  We 
and others have shown that matrix metalloproteinase-2 (MMP-2) and MMP-9 are elevated in 
laminitic laminae12-17.  The concentration of MMP-9 in laminitic laminae correlates directly with 
the number of inflammatory leukocytes12,17  suggesting these cells are the source of the enzyme.  
In contrast, the concentration of MMP-2 bears no relationship to that of inflammatory 
leukocytes or MMP-918  suggesting production by a cell that is endogenous to the laminae.  
MMP-9 is present in inactive zymogen form only and hence may be of little relevance to the 
disease process.  However, much of the MMP-2 is present as an active form, which is 
significantly elevated in the laminae of horses with OG3 lameness when analyzed as a group 
although some horses develop severe laminitis in the absence of elevated laminar MMP-218.  
These observations indicate that MMP-2 is not the sole cause of laminar degradation.  
Furthermore, more recent studies show that there is little or no MMP-2 activity present in 
extracts of laminae collected from horses during the developmental and OG1 stages of lameness 
(Wang and Black, unpublished), suggesting that MMP-2 may have a role at the time of 
catastropic breakdown of the laminae only, or in attempts by the tissue to repair this process.     
The lack of correlation between MMP-9 and MMP-2 expression and the development of 
laminitis in the face of obvious ECM injury in the disease process led us to examine a broader 
group of metallopoteinases and to characterize the types and distributions of the main lamellar 
ECM components (collagens, laminins, proteoglycans and glycosaminoglycans).  These studies 
showed that expression of the gene encoding ADAMTS-4 is elevated (~100 fold) in the laminae 
of horses with black walnut toxin- and starch gruel-induced laminitis and in laminae of horses 
with naturally acquired disease and is not accompanied by elevated expression of genes 
encoding tissue inhibitors of metalloproteinases (TIMPs)19.   
 4 
 These data led us to hypothesize that the substrates of ADAMTS-4, namely, aggrecan 
and versican, were not only present in the equine digital laminae, but that loss of these 
proteoglycans would be a critical pathological feature of equine laminitis.  In following this 
hypothesis, we have created an extensive molecular characterization of the pathogenesis of 
laminitis in the CHO model system, which will be detailed in the following chapters of this 
dissertation. 
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1.1 Chapter 1 Figures 
 
Figure 1.1 
Gross Anatomy of the Equine Digital Laminae (Design: Chris Pollitt, Art. John McDougall): The 
Figure is reproduced by permission of Dr. C. Pollitt.  Sections of laminae presented in this 
dissertation are from the mid dorsal front hoof laminae and the region is delineated by the oval 
shown in this figure. 
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CHAPTER 2 
 
DISTRIBUTION AND PROCESSING OF ADAMTS-4, AGGRECAN, VERSICAN, AND 
HYALURONAN IN THE EQUINE DIGITAL LAMELLAE 
2.1 Introduction 
The equine digital laminae span between the surface of the distal phalanx and the inner 
hoof wall.  Laminae are composed of 500 to 600 vertical folds of keratinized epidermal tissue, 
the primary epidermal laminae, which are contiguous with the inner hoof wall, and 
interdigitated folds of connective tissue, the primary dermal laminae, which are contiguous with 
the distal phalanx1.  Each fold of primary epidermal and dermal laminae has 150 to 200 
interdigitated folds of secondary laminae resulting in a greatly expanded contact area between 
these tissue layers.  The secondary epidermal and dermal laminae join at a basement 
membrane, which is a meshwork of collagen fibers and laminins cross-linked and anchored via 
hemidesmosomes to basal epithelial cells residing at the boundary of the epidermal laminae2.  
The basement membrane is tethered to tensile collagen fibers of the dermal laminae, which are 
bound by a variety of extracellular matrix components to each other and to integrins expressed 
by cells on both sides of the membrane20, thus ensuring integrity of the two layer structure.  The 
basal epithelial cells, or stem cells within this population, give rise to keratinocytes which move 
outward towards the hoof wall and, analogous to skin epidermal cells, increase their keratin 
content, generate a cornified cell envelope and undergo terminal differentiation21,22.   
The digital laminae resist force imposed by the deep flexor tendon through the distal 
phalanx to the dermal attachments to the bone23-25.  They also support the vertical load of the 
horse and accommodate compression and stretch deformation created by the flexing, twisting 
and tilting of the hoof capsule under different loading conditions.  In addition, the laminae 
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absorb a portion of the concussive shock imposed when the hoof strikes a solid surface.  
Concussive shock most likely dissipates in the hoof by freedom of movement of hydrated keratin 
fibers within the epidermal laminae and transfer of load from the hoof wall to the dermal 
connective tissue and distal phalanx through the basal epithelial cell layer. Basal epithelial cells 
are therefore subjected to biomechanical stress and concussion waves of varying amplitude and 
frequency.   
 Analyses in model systems show that cells adapt to constant and discontinuous 
mechanical stress through mechanoreceptor signaling26,27.  In this regard, chondrocyte explants 
that are subjected to dynamic compression within a tolerable range respond by elevated 
extracellular matrix production26 including elevated production of large polysulfated 
proteoglycans.  Since the equine digital laminae are also subject to dynamic 
compression/stretching they may also have a highly specialized extracellular matrix that is rich 
in polysulfated proteoglycans.  Indeed, the gene encoding ADAMTS-4, which is a secreted 
enzyme that regulates turnover of large polysulfated proteoglycans in the extracellular matrix, is 
expressed in laminae of healthy horses28, which suggests that its substrates may also be present 
in the tissue. 
 The main substrates of ADAMTS-4 in peripheral tissues are aggrecan and versican29.  
These proteoglycans have glycosaminoglycan attachment domains that can be heavily 
substituted with chondroitin sulfate side chains, and, in the case of aggrecan, also keratan 
sulfate side chains30-32.  Both aggrecan and versican have a hyaluronan binding site in the N 
terminal G1 domain, which facilitates assembly of massive and highly charged macromolecular 
complexes in the extracellular matrix.  The anionic groups on the glycosaminoglycans carry with 
them positively charged counter ions, such as Na+, creating an osmotic gradient and drawing 
water into the tissue.  The resulting hydrated gel protects tissue from compression 
 8 
deformation30,33,34. Given that laminae express the gene encoding ADAMTS-4 and are subjected 
to biomechanical and concussion stress, it was of interest to determine expression and 
localization patterns of ADAMTS-4 and its proteoglycan substrates in the laminae.  Here we 
report that ADAMTS-4 and its substrates are indeed present in healthy laminae, but, 
unexpectedly, localize within basal epithelial cells of the secondary epidermal laminae rather 
than in the extracellular matrix.  
 
2.2 Results 
2.2.1 Gene Expression 
Genes encoding ADAMTS-4, aggrecan, versican and hyaluronan synthase II are 
expressed in the equine digital laminae of 8 healthy horses as determined by RT-qPCR. Primer 
sets are described in table 1 and each generated a single product of expected size (Appendix B, 
representative results are shown in Fig 2.1; Lane 2 aggrecan; Lane 3 versican; Lane 4 hyaluronan 
synthase II; Lane 5 ADAMTS-4 N terminal domain; Lane 6 ADAMTS-4 C-terminal domain; Lane 7 
GAPDH; Lane 8 blank control) and sequence (data not shown).    Mean Ct values +/- 1 standard 
deviation were: GAPDH 21.82+/- 0.88, aggrecan 29.02+/-1.37, versican 25.84+/- 1.20, 
hyaluronan synthase II 30.34 +/- 0.94, ADAMTS-4 (N-terminal domain primers) 34.12 +/- 1.57, 
ADAMTS-4 (C-terminal domain primers) 32.45 +/- 1.054.  No Ct value was recorded for the blank 
control. 
Versican is composed of 4 domains, namely an N terminal G1 domain, which has the 
hyaluronan binding site, a αGAG domain which has sites for attachment of chondroitin sulfate 
side chains, a βGAG domain which also has sites for attachment of chondroitin sulfate side 
chains and a lectin like C terminal domain, which has 2 epidermal growth factor-like motifs35.  
Four splice variants (isoforms) of versican are made comprising the V0 isoform which has all 4 
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domains ordered as above; the V1 isoform which has G1, βGAG and C domains only; the V2 
isoform which has G1, α GAG and C domains only; and the V3 isoform which has G1 and C 
domains only and therefore lacks glycosaminoglycans36. Comparative RT-qPCR analyses 
performed with primer sets specific for equine versican G1, αGAG, βGAG and C terminal 
domains showed ratios close to 1:1:1:1 (data not shown) consistent with expression of the full 
length gene. In addition, RT-PCR analyses performed with primer sets specific for equine V0 
versican - αGAG/βGAG (Fig 2.2, lane 2),  V1 versican - G1/βGAG (Fig 2.2, lane 3), V2 versican - 
G1/αGAG (Fig 2.2, lane 4), and V3 versican - G1/C (Fig 2.2, lane 5) showed that spliced sequence 
encoding V0 and V1 versican isoforms were abundantly present in laminae while those encoding 
the V2 isoform were less abundant and spliced sequence encoding the V3 isoform were not 
detected.  Primer specificity was confirmed by sequencing the products (not shown). 
2.2.2 Protein Expression 
Extracts from the 8 laminae were subjected to Western blotting following SDS-PAGE  
(Appendix A) to determine the protein expression of ADAMTS-4 and its substrates.  
Representative results are presented in Figure 2.3.   
2.2.2.1 ADAMTS-4 
Proteins in NP-40 extract of laminae were subjected to SDS-PAGE and ADAMTS-4 was 
detected by Western blotting using an antibody specific for the catalytic site cleavage 
neoepitope FASLSRFVET which is revealed only upon removal of the regulatory propeptide37.  
Results are presented in Figure 2.3A and show that processed ADAMTS-4 is predominantly 
present as a ~51 kDa polypeptide accompanied by a ~41 kDa form.  The ~51 kDa polypeptide 
was detected in all 8 laminae extracts analyzed, while the ~41 kDa polypeptide was detected in 
only 6 of 8 laminae extracts analyzed.  The same results were obtained when samples of 
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pulverized laminae were directly solubilized in SDS-sample buffer (data not shown) showing that 
processing of ADAMTS-4 by propeptide convertase38,39, which exposes the FASLSRFVET catalytic 
site neoepitope, was not an extraction artifact. 
2.2.2.2 VO/V1 Versican 
To explore versican protein expression, NP-40 laminae extracts of laminae were subjected 
to SDS-PAGE and ADAMTS-4 V0/V1 versican cleavage fragments were revealed by Western 
blotting using an antibody specific for the C terminal V0/V1 versican β GAG domain neoepitope 
DPEAAE.   Results are presented in Figure 2.3B and show V0/V1 versican fragments of ~109 kDa 
and ~66kDa.  Detection of the polypeptides was abrogated when anti-DPEAAE antibodies were 
pre-incubated with sense peptide but not antisense peptide (data not shown). The ~109 kDa 
polypeptide was detected in 6 of 8 laminae extracts analyzed, while the ~66kDa polypeptide was 
detected in all 8 laminae extracts analyzed.  Polypeptide bands of similar size were detected 
when pulverized laminae was directly solubilized in SDS-sample buffer (data not shown) 
showing that processing of V0/V1 versican by ADAMTS-4 was not an extraction artifact. 
2.2.2.3 V0/V2 Versican 
NP-40 laminae extracts were subjected to SDS-PAGE and ADAMTS-4 V0/V2 versican 
cleavage fragments revealed by Western blotting using an antibody specific for the C terminal 
V0/V2 versican α GAG neoepitope NIVSFE .  Results are presented in Figure 2.3C and show 
V0/V2 versican fragments of ~112 kDa and ~68 kDa.  The polypeptides were detected in all 8 
laminae extracts analyzed and detection of bands was abrogated when antibodies were pre-
incubated with sense peptide but not antisense peptide (data not shown).  Polypeptide bands of 
similar size were detected when tissue was directly solubilized in SDS-sample buffer (data not 
shown) showing that processing of V0/V2 versican by ADAMTS-4 was not an extraction artifact. 
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2.2.2.4 Aggrecan 
SDS-PAGE analysis of ADAMTS-4 fragments of aggrecan required their extraction from 
pulverized laminae by guanidine hydrochloride buffer, precipitation with ethanol and 
subsequent digestion with hyaluronidase, chondroitinase ABC and keratanase (data not shown).  
These treatments were necessary because aggrecan ADAMTS-4 cleavage fragments: i) were not 
extracted from pulverized laminae by incubation with NP-40 buffer, ii) co-extracted with their 
binding partner hyaluronan in guanidine hydrochloride buffer, and were held in an insoluble 
hyaluronan gel upon replacement of guanidine hydrochloride with water or physiological buffer, 
iii) were heavily glycosylated, particularly with chondroitin sulfate glycosaminoglycans, which 
prevented migration through the stacking gel in SDS-PAGE in the absence of appropriate 
digestion.  Western blotting performed following SDS-PAGE of the hyaluronidase, 
chondroitinase ABC and keratanase digested guanidine hydrochloride extracted  material using 
an antibody specific for the aggrecan N terminal ADAMTS-4 cleavage neoepitope ARGSVIL 
revealed bands at ~318 kDa, ~250 kDa, ~150 kDa and ~70 kDa (a representative result is shown 
in Fig 2.3D).   These polypeptide bands were detected in the 8 laminae extracts analyzed. 
2.2.3 Immunohistological evaluation 
To determine the cellular localization of ADAMTS-4 and its substrates, immunohistological 
studies were performed on flash frozen OCT-embedded laminae (n=6). All samples were 
analyzed for each staining protocol and representative results are shown below.        
2.2.3.1 General Structure 
A thin transverse section of frozen digital laminae stained with a pan-laminin specific 
antibody revealed by a texas red-conjugated secondary antibody (red), and with the DNA 
intercalating dye DAPI (blue), is shown in Figure 2.4 A.  Laminin is a component of the basement 
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membrane which lies at the junction between the secondary epidermal and dermal laminae.  
Laminin is also a component of the basement membrane of small blood vessels which can be 
seen as small red open circles in the secondary dermal laminae, and of blood vessels in the 
primary dermal laminae.  DAPI (blue) stained cell nuclei can be seen throughout the tissue and 
those of the basal epithelial cells abutting the basement membrane.  Some tissue components, 
putatively collagen fibers in primary and secondary dermal laminae, autofluoresce green at the 
excitation wavelength (488nm) used in the studies (Fig 2.4A).  This autofluorescent material can 
also be seen in Figures 2.5A, 2.5B, Figure 2.6A and Figure 2.7A, has a relatively weak signal 
which is not digitally recorded when a bright green fluorescent signal is obtained following 
appropriate specific staining, e.g., after staining thin frozen sections with FITC-phalloidin as 
shown in Figure 4B and discussed below. 
Additionally, a section of frozen digital laminae stained with FITC-phalloidin (green) to 
detect actin bundles and DAPI (blue) to detect DNA in nuclei is shown in Figure 2.4B.  The FITC-
phalloidin is most densely associated with the cortical actin skeleton of basal epithelial cells (the 
outermost cell layer of the secondary epidermal laminae; Fig 2.4B), but can also be seen defining 
the cortical actin skeleton of suprabasal cells extending into the primary epidermal laminae (Fig 
2.4B).  Note that DAPI (blue) stained nuclei are faded or absent from keratinocytes in the 
primary epidermal laminae.   The contiguous keratinocyte cortical actin network evident 
throughout the secondary epidermal laminae indicates that there is little room for extracellular 
matrix in this tissue.  The phalloidin-FITC stain is bright and very little exposure time was 
required to capture the image shown in Figure 2.4B, accounting for the almost complete 
absence in the captured image of the green autofluorescent materials seen in Fig 2.4A. 
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2.2.3.2 Versican 
A thin transverse section of frozen digital laminae stained with antibody specific for the 
carboxy-terminal domain of all versican isoforms revealed with a secondary antibody 
conjugated with a proprietary red dye, and with the DNA intercalating dye DAPI (blue), is shown 
in Figure 2.5A.  It is notable that versican staining is restricted to a single layer of cells, putatively 
the basal epithelial cells. Specific staining of versican was inhibited by pre-incubation of the 
antibody with its competing peptide (Fig 2.5B) but not with an antisense peptide (not shown).   
Identification of the versican-stained (red) cell layer as basal epithelial cells was confirmed by 
showing that the cells are adjacent to the basement membrane.  This was achieved by staining a 
thin section of frozen laminae with: i) pan-anti-laminin antibody revealed here by a secondary 
antibody conjugated with a proprietary green fluorescent dye, ii) anti-versican antibody 
revealed by red fluorescent dye -conjugated secondary antibody and iii) with DAPI which stains 
nuclei blue.  Results are presented in Figure 2.5C.  The versican (red) does not actually contact 
(co-localize with) basement membrane laminin (green), which would have given a yellow 
merged image. To test whether versican is contained with basal epithelial cells, a thin 
cryosection was co-stained with anti-versican antibody which was detected using a texas red-
conjugated secondary antibody (red) and the section was also stained with FITC-phalloidin to 
detect actin bundles (green) and with DAPI (blue) to detect cell nuclei.  Results presented in 
Figure 2.5D show that versican (red) is located between the cortical actin of basal epithelial cells 
(green) and the cell nuclei (blue).  In addition, it is clear that versican staining is not pronounced 
along cell boundaries suggesting little or no accumulation of the proteoglycan in extracellular 
space. 
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2.2.3.3 Aggrecan 
A representative thin transverse section of frozen digital laminae was stained with antibody 
that reacted with an epitope on the G2 domain of aggrecan revealed with a proprietary red 
fluorescent dye-conjugated secondary antibody, and co-stained with DAPI (blue) (Figure 2.6A).  
Aggrecan staining (red) was greatest in basal epithelial cells but was also detected in regions of 
the epidermal laminae occupied by supra-basal epithelial cells.  Aggrecan was largely, if not 
entirely, absent from primary and secondary dermal laminae.  Autofluorescent material 
(putatively collagen; green) is readily seen in this image.  Aggrecan staining was inhibited by pre-
incubation of the antibody with its competing peptide (Fig 2.6, inset B).   To further identify the 
distribution of aggrecan in laminae, a transverse thin frozen section was co-stained with 
aggrecan specific antibody (red), FITC-phalloidin (green) to detect actin bundles and DAPI (blue) 
to detect nuclei.  Aggrecan staining (red) was present within punctuate bodies contained within 
boundaries defined by phalloidin stained cortical actin (green) (Fig 2.6, inset C).  A similar tissue 
distribution was seen in immunohistological sections stained with the antibody against the 
“ARGSVIL” epitope of aggrecan (data not shown). 
2.2.3.4 Hyaluronan 
A representative thin transverse section of frozen digital laminae was stained with antibody 
specific for hyaluronan polysaccharide revealed with texas red-conjugated secondary antibody 
(red), and co-stained with DAPI (blue).  Results are shown in Figure 2.7A which shows that 
hyaluronan (red) is diffusely present in the epidermal laminae and is not pronounced along cell 
boundaries (Fig 2.7A).  Staining was absent from tissue sections that had been pre-treated with 
hyaluronidase (Fig 2.7, inset B).  Hyaluronan staining within the secondary epidermal laminae 
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was contained within cell boundaries defined by phalloidin stained cortical actin (green) (Fig 2.7 
inset C). 
2.2.3.5 ADAMTS-4 
Thin transverse sections of frozen digital laminae were stained with an antibody specific to 
the peptide “NTPEDSDPDHFD” corresponding to amino acids 300-311 of the metalloprotease 
domain of equine ADAMTS-4.  ADAMTS-4 staining was revealed with a red fluorescent dye-
conjugated secondary antibody and nuclei counterstained with DAPI (blue).  Antibody specificity 
was confirmed by western blotting, which revealed similar band patterns to those obtained 
using the “FASLSRFVET” ADAMTS-4 antibody (shown in Fig 2.3A) and by inhibition of Western 
blotting with sense but not antisense peptide (data not shown). 
 Staining was diffusely present throughout the epithelial cells of the secondary epidermal 
lamellae (Figs 2.8A and B), and was abrogated by pre-incubation of the antibody with its 
immunizing peptide (Fig 2.8A, inset) but not with a non-competing peptide (data not shown).  
Punctate staining was also present in cells associated with the vasculature (Fig 2.8A, white 
arrow), mononuclear cells of the dermal lamellae (Figs 2.8A and B, blue arrows), and dermal 
fibroblasts (Fig 2.8B, yellow arrows).  
2.3 Discussion 
Using RT-qPCR and validated primers we show that equine digital laminae express genes 
encoding ADAMTS-4, aggrecan, versican (processed to V0, V1 and V2 splice isoforms) and 
hyaluronan synthase II.  Using SDS-PAGE followed by Western blotting with antibodies specific 
for conserved peptides in horse and human ADAMTS-4, aggrecan and versican, and validated by 
peptide competition, we confirmed that gene expression is accompanied by protein expression 
and that the core proteins of the large polysulfated proteoglycans are subject to constitutive 
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ADAMTS-4 cleavage in vivo. Using immunofluorescent and immunohistochemical staining of thin 
sections of laminae with specific antibodies validated by peptide competition or targeted 
epitope digestion, we show that aggrecan, versican and hyaluronan are predominantly present 
within basal epithelial cells of the secondary epidermal laminae, while ADAMTS-4 is present 
within these cells and also in cells of the dermal laminae.  
In all laminar extracts, ADAMTS-4 was present predominantly as a ~51 kDa form bearing 
the conserved FASLSRFVET neoepitope, which is exposed upon removal of regulatory 
propeptide by furin propeptide convertase in the trans golgi38.  A minor ~61 kDa form bearing 
the neoepitope was also detected in all samples but staining was too weak to be visible in the 
images presented.  In addition, a ~42kDa form of ADAMTS-4 bearing the FASLSRFVET 
neoepitope was detected in extracts from 75% of samples tested.  Processed ADAMTS-4 bearing 
the FASLSRFVET neoepitope has a MW between ~68 kDa and 70 kDa in mice and humans and a 
portion of the material undergoes autoproteolysis to generate ~61 kDa, 51 kDa and 40 kDa 
polypeptides34,40,41 corresponding to the  ~61 kDa, ~51 kDa, ~42 kDa laminae material reported 
here.  The absence of the ~68 kDa– 70 kDa enzyme from extracts of laminae suggests that 
autoproteolytic activity of equine ADAMTS-4 may be greater than that of murine and human 
ADAMTS-4.   
In addition to cleaving the large polysulfated proteoglycans, autoproteolysed ADAMTS-4 
has been shown to cleave low molecular weight leucine rich proteoglycans which bind collagens 
and fibronectin, affecting fiber formation and network organization41,42.  Thus, in the equine 
digital laminae, ADAMTS-4 may cause the re-organization of a broad range of ECM components.  
This increased cleavage capability may have implications for the development of laminitis. 
Aggrecan is a highly glycosylated multidomain protein33.  The core protein of ~220 kDa can be 
decorated with up to 100 chondroitin sulfate side chains each of ~20 kDa positioned between 
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globular domains 2 and 3.  Aggrecan can also be decorated with up to 60 keratin sulfate side 
chains each of ~5 kDa to ~15 kDa which are more widely distributed on the molecule than the 
chondroitin sulfate glycosaminoglycans. In addition, a variable number of O- and N-linked 
oligosaccharide side chains can also be added.  ADAMTS-4 cleaves aggrecan between the G1 and 
G2 domains at the Glu373-Ala374 bond yielding a large glycosaminoglycan rich fragment with an N 
terminal ARGSVI cleavage neoepitope and a G1 fragment with a NITEGE neoepitope.  Antibodies 
specific for ARGSVIL detected polypeptides of ~318 kDa, ~250 kDa, ~150 kDa and ~70 kDa, 
present in guanidine hydrochloride extracts of laminae that were further subjected to 
hyaluronidase/chondroitinase ABC digestion. The largest fragments most likely correspond to N 
or O glycosylated material.  This presence of polypeptides bearing the ADAMTS-4 cleavage 
neoepitope in lamina extracts indicates that endogenous ADAMTS-4 is active in the laminae.   
Cleavage of aggrecan between Glu373-Ala374 by ADAMTS-4 and ADAMTS-5 in cartilage allows 
large glycosaminoglycan rich fragments, which are no longer anchored to hyaluronan, to diffuse 
into synovial fluid43.  However, constitutive cleavage of aggrecan in the laminae did not allow 
the ARGSVI positive glycosaminoglycan-rich fragments to easily detach from the tissue, inferred 
from our inability to extract the fragments into NP-40 homogenization buffer.  Rather, overnight 
incubation of pulverized laminae in a 4M guanidine hydrochloride extraction buffer was 
required to extract the cleavage fragments suggesting that they are held in the lamellar tissue 
by interactions with other as yet unidentified molecules. 
NP-40 and direct SDS sample buffer extracts of pulverized laminae contain V0/V1 
versican fragments of ~109 kDa and ~66 kDa bearing the C terminal β GAG domain ADAMTS-4 
cleavage neoepitope DPEAAE.  The MWs of these fragments are unaffected by digestion with 
hyaluronidase or chondroitinase ABC and hence the fragments do not have attached hyaluronan 
or chondroitin sulfate glycosaminoglycans.  It is likely that the ~66 kDa fragment described here is 
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equivalent to the ~70 kDA DPEAAE positive G1 domain of versican V1 reported to be present in 
ADAMTS-4 treated human aorta44.  The extracts of laminae also contained ~112 kDa and ~68 kDa 
V0/V2 versican fragments bearing the C terminal ADAMTS-4 α GAG domain cleavage neoepitope 
NIVSFE.  ADAMTS-4 cleavage of fully deglycosylated human aorta V0/V2 versican has been shown 
to yield an NIVSFE positive fragment of ~64 kDa which is equivalent to the glial hyaluronate 
binding protein of human brain V2 versican45.  Although we digested extracts of laminae with 
chondroitinase ABC we did not digest with sialidase or O-glycanase perhaps accounting for the 
larger sized (~68 kDa) putative versican G1- α GAG domain fragment detected in our studies.  The 
~112 kDa material is however too large to be comprised solely of the ADAMTS-4 cleaved versican 
G1 and α GAG core protein domains, suggesting that it may be heavily N-glycosylated.  The ~112 
kDa and ~68 kDa polypeptides bearing the NIVSFE neoepitope were also detected (data not 
shown) by antibodies raised against the N-terminal 13-residue peptide sequence of human 
versican (LF-9946 , a gift from Dr. Larry Fisher, NIH) which is 87% homologous to matched equine 
sequence further supporting their identify as fragments of versican.   
Aggrecan and versican have been extensively studied in articular cartilage, tendons, and 
atherosclerotic plaque where they associate with hyaluronan in the extracellular matrix 
(ECM)29,33,47.  Hyaluronan is a non-sulfated glycosaminoglycan that is synthesized at the plasma 
membrane by one of three distinct hyaluronan synthases48 and extruded into the extracellular 
space.  Hyaluronan synthase II, which was shown here to be expressed in the laminae, makes 
the longest hyaluronan chains, which can be larger than 2000 kDa.  Hyaluronan binds a large 
number of aggrecan monomers with binding stabilized by link protein.  These complexes can 
reach several hundred millions of Daltons30.  The large negatively charged complexes of 
aggrecan and hyaluronan attract and hold water in tissues, forming a hydrated gel.  This is 
packaged in collagen fibers in articular cartilage and tendon, accounting for the high resistance 
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of these tissues to compression deformation33.  Versican is also a hyaluronan-binding 
proteoglycan.  It is expressed in fast growing cells of many tissues including the skin, the media 
of the aorta and in developing chicken limb buds49, where it is implicated in regulating cell 
proliferation and migration as well as in expanding the ECM and increasing its viscoelasticity.  
Given these data, it was expected that aggrecan, versican and hyaluronan in the digital laminae 
would also be associated with ECM as well as present in producer cells.  However, the materials 
were not observed to be present in the ECM.  Furthermore the secondary epidermal laminae 
had little to no discernable ECM.   
Aggrecan was detected in punctuate bodies contained within cortical actin boundaries 
throughout the basal and suprabasal epithelial cells of the secondary epidermal laminae.  
Hyaluronan staining was also present in punctuate bodies contained within cortical actin 
boundaries throughout the secondary epidermal laminae.  In contrast, versican staining was 
restricted to basal epithelial cells only.  Versican was not detected in any suprabasal epithelial 
cells in the secondary epidermal laminae.  Thus, our studies suggest that versican, aggrecan and 
hyaluronan may be useful markers for defining specialization within epidermal keratinocytes.   
In addition to aggrecan, versican and hyaluronan, basal epithelial cells also contained ADAMTS-
4.  Because versican fragments bearing an ADAMTS-4 neoepitope were readily extracted from 
laminae into SDS sample buffer, which prevents post extraction processing, it can be concluded 
that a portion if not all versican and ADAMTS-4 share an intracellular compartment that permits 
ADAMTS-4 activity.  Furthermore, because aggrecan fragments bearing an ADAMTS-4 
neoepitope could also be extracted from laminae, it is likely that at least a portion of aggrecan 
and ADAMTS-4 also share an intracellular compartment that permits ADAMTS-4 activity.  Thus, 
ADAMTS-4 contributes to processing, and most likely turnover of aggrecan and versican within 
laminar basal epithelial cells.   
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The biological roles of aggrecan, versican, hyaluronan and ADAMTS-4 in equine digital 
laminae are not directly illuminated by the above studies.  However, based on known 
compression-resistance and cell signaling properties of the large polysulfated proteoglycans it is 
reasonable to propose that the proteoglycans affect development and maintenance of the basal 
epithelial cell layer, and may cushion basal epithelial cells against the severe biomechanical 
stresses associated with their anatomical location.  
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2.4 Chapter 2 Figures 
 
Figure 2.1 
Analysis of RT-qPCR Products for ADAMTS-4 and Substrates:  Lane 1, DNA marker (100 bp 
ladder); Lane 2 aggrecan; Lane 3 versican; Lane 4 hyaluronan synthase II; Lane 5 ADAMTS-4 N 
terminal domain; Lane 6 ADAMTS-4 C-terminal domain; Lane 7 GAPDH; Lane 8 blank control. 
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Figure 2.2 
Analysis of PCR Products for Versican Isoforms: Lane 1, DNA marker (100 bp ladder); Lane 2, 
V0; Lane 3, V1; Lane 4, V2; Lane 5, V3. 
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Figure 2.3  
Immunoreactivity of ADAMTS-4 and its Substrates: Western blots of laminar extracts (30 μg 
protein/lane) were probed using: A) antibody against neoepitope FASLSRFVET exposed on 
ADAMTS-4  catalytic domain after removal of the regulatory propeptide (NP-40 extract); B) 
antibody against versican V0/V1 neoeptiope DPEAAE generated by ADAMTS-4 cleavage (NP-40 
extract); C) antibody against versican V0/V2 neoeptiope NIVSFE generated by ADAMTS-4 
cleavage (NP-40 extract); D) antibody against aggrecan neoepitope ARGSVIL (BC-3) generated by 
ADAMTS-4 cleavage (guanidine hydrochloride extract digested with hyaluronidase, 
chondroitinase ABC and karatinase III). 
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Figure 2.4 
 Defining Lamellar Structure via Localization of Laminin and Actin: A) Epidermal/dermal 
lamellar boundary is visualized by immunofluorescent staining against the basement membrane 
marker laminin in red.  Autofluorescent material (putatively collagen) in green, nuclei stained 
blue; B) Epidermal cellular boundaries visualized with staining against actin in green, nuclei 
stained blue. The images are representative of samples from 6 animals analyzed. Scale bars 
50μm. 
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Figure 2.5 
Versican Localization in the Basal Epithelium of the Secondary Epidermal Lamellae: A) 
Immunofluorescent staining against versican in red, autofluorescent material in green, nuclei 
stained blue; B) versican staining blocked by pre-incubation of primary antibody with cognate 
peptide, autofluorescent material in green, nuclei stained blue; C) versican staining in red, 
basement membrane visualized by staining against laminin in green, nuclei stained blue; D) 
versican staining in red, epithelial cell boundaries visualized by staining against actin in green, 
nuclei stained blue. The images are representative of samples from 6 animal analyzed. Scale 
bars 50μm. 
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Figure 2.6 
 Aggrecan Localization in the Secondary Epidermal Lamellae: A) Immunofluorescent staining 
against aggrecan in red, autofluorescent material in green, nuclei stained blue; B) aggrecan 
staining was blocked by preincubation of the primary antibody with cognate peptide, 
autofluorescent material in green, nuclei stained blue; C) aggrecan staining in red, epithelial cell 
boundaries visualized by staining against actin in green, nuclei stained blue. The images are 
representative of samples from 6 animals analyzed. Scale bars 50μm. 
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Figure 2.7 
Hyaluronan Localization in the Secondary Epidermal Lamellae: A) Immunofluorescent staining 
against hyaluronan in red, autofluorescent material in green, nuclei stained blue; B) hyaluronan 
staining abrogated by incubation of tissue section with epitope-digesting enzyme 
(Chondroitinase ABC pH 6.8), autofluorescent material in green, nuclei stained blue; C) 
hyaluronan staining in red, epithelial cell boundaries visualized by staining against actin in green, 
nuclei stained blue. The images are representative of samples from 6 animals analyzed. Scale 
bars 50μm. 
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Figure 2.8  
ADAMTS-4 Localization in the Secondary Epidermal Lamellae: A) Immunofluorescent staining against ADAMTS-4 “NTPEDSDPDHFD” epitope in 
red, autofluorescent material in green, nuclei stained blue. Staining blocked by cognate peptide in inset. B) Higher magnification image, 
ADAMTS-4 visualized in red, autofluorescent material in green, nuclei in blue. Images representative of samples from 6 animals analyzed.  Scale 
bars 50μm.  White arrows indicate vascular endothelia, blue arrows indicate mononuclear cells of the dermal lamellae, yellow arrow indicates a 
dermal fibroblast. 
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CHAPTER 3 
 
CLEAVAGE BY ADAMTS-4 AND GENE REPRESSION DEPLETE VERSICAN FROM THE DIGITAL 
LAMINAE OF HORSES WITH STARCH GRUEL-INDUCED LAMINITIS 
3.1 Introduction 
Histologic analyses of laminae from laminitic horses show several pathologic features that 
may contribute to their failure.  These include increased apoptosis of basal epithelial cells50, 
reduced presence of hemidesmosomes in basal epithelial cells resulting in diminished 
attachment to the basement membrane and loss of anchoring filaments that attach the 
basement membrane to adjacent fibrillar collagen2,51.  In addition, sections of laminae from 
laminitic horses show infiltration of the dermal laminae by inflammatory leukocytes53,54 and 
development of regions within the secondary dermal laminae that lack both cellular and 
extracellular matrix (ECM) components (Pawlak and Black, unpublished, see Chapter 5) 
consistent with enzymatic degradation.  Identifying physiological changes in basal epithelial cells 
that cause their detachment from the basement membrane or apoptosis, as well as the 
enzymes that mediate damage to the basement membrane and its adjacent ECM are essential 
steps towards developing effective therapies.   
We and others have shown that pro-matrix metalloproteinase (MMP)-9, pro-MMP-2 and 
MMP-2 are elevated in laminae of horses with naturally acquired laminitis and in some models 
of experimentally induced laminitis13,15,53,55,56.  Invariably, the concentration of pro-MMP-9 in the 
laminae correlates with the presence and the myeloperoxidase signature of inflammatory 
leukocytes53,56 whereas expression of pro-MMP-2 and MMP-2 bears no relationship to the 
concentration of myeloperoxidase or to the concentration of pro-MMP-9. This suggests that the 
pro-MMP-2 is produced by a cell other than an inflammatory leukocyte53.  The regulatory pro-
Fig 1 
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peptide of pro-MMP-9 typically blocks access to the active site, but conformational changes 
induced by binding of pro-MMP-9 to substrate, or by oxidative modification of pro-MMP-9, can 
permit catalytic activity without proteolytic removal of the pro-peptide57,58.  However, although 
there is evidence of lipid peroxidation in laminitic laminae59, there is no evidence that pro-MMP-
9 is oxidized or active in the laminae.  Indeed, there is little evidence of laminar degradation in 
horses with OG1-lameness even when the laminae of these animals contain large numbers of 
immigrant neutrophils and highly elevated levels of pro-MMP-956.   
An elevated level of MMP-2 in the laminae is a characteristic of horses with chronic 
relapsing laminitis and with starch gruel-induced laminitis at OG3-lameness53.  However, little or 
no MMP-2 is present at OG1-lameness in horses with BWE-induced56 or starch gruel-induced 
lameness (Wang and Black, unpublished data).  Thus, MMP-2 may contribute to the 
deterioration of the laminae in severe disease only, or may be induced as a component of a 
repair response.  Furthermore, whereas the concentration of MMP-2 is significantly elevated in 
the laminae of horses with starch gruel-induced laminitis at OG3-lameness compared to that in 
healthy horses, some horses develop starch gruel-induced OG3-lameness in the absence of 
elevated laminar MMP-2 and an occasional control horse can express a high level of MMP-2 in 
the laminae without showing signs of lameness53.  Thus, metalloproteinases other than MMP-2 
and MMP-9 are likely to contribute to degradation of the laminae in laminitis.  
We have recently reported that the gene encoding ADAMTS-4 is expressed in the laminae of 
healthy horses and over-expressed in the laminae of horses with experimentally induced (black 
walnut heartwood toxemia and starch gruel overload models) and naturally acquired laminitis28.  
Furthermore, we have shown that ADAMTS-4 protein is constitutively expressed in the laminae 
of healthy horses as a 51 kDa form60.  Catalytic activity was inferred both by catalytic site 
neoepitope exposure, which is indicative of prior removal of the regulatory propeptide, and by 
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the presence in the tissue of ADAMTS-4 cleavage fragments of aggrecan and versican60.  
Aggrecan and versican are large polysulfated proteoglycans and primary substrates of ADAMTS-
429,61,62.   Anionic groups on their glycosaminoglycan (GAG) side chains carry with them positively 
charged counter ions, such as Na+, creating an osmotic gradient and drawing water into the 
tissue.  In combination with hyaluronan the proteoglycans form hydrated gels that endow 
tissues with resistance to compression deformation30,34,61.  In addition, aggrecan and versican 
have signaling properties that affect cell proliferation, differentiation, adhesion and intercellular 
communication49,62,63 and hence have additional, non-mechanical, roles in regulating cell 
function.   
In healthy horses aggrecan and hyaluronan are present throughout the digital secondary 
epidermal laminae and enriched within the basal epithelial cell layer, which abuts the basement 
membrane60.  Versican has a more restricted distribution than aggrecan, localizing solely to the 
basal epithelial cells.  Based on their biochemical and biological properties and on their tissue 
distribution, it is feasible that the proteoglycans affect development and maintenance of the 
basal epithelial cell layer as well as cushion basal epithelial cells against the severe 
biomechanical stresses associated with their anatomical location.  Elevated ADAMTS-4 gene 
expression in laminitic laminae28, if it is accompanied by elevated enzyme expression and 
degradation of its proteoglycan substrates, may therefore play a critical role in failure of the 
laminae.   
Here we show that elevated expression of the gene encoding ADAMTS-4 in laminitic laminae 
is accompanied both by an increase in the amount of ADAMTS-4 protein in the tissue and by 
increased amounts of fragments of versican bearing ADAMTS-4 cleavage-neoepitopes.  
Furthermore, in severely laminitic laminae, expression of the gene encoding versican is 
drastically reduced and versican is substantially depleted from the basal epithelial cell layer.  The 
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studies show a dramatic change in versican expression and processing in the basal epithelium of 
laminitic laminae, which may compromise basal epithelial cell function and the association of 
epidermal and dermal layers of the laminae. 
3.2 Results 
3.2.1 Gene Expression 
3.2.1.1 ADAMTS-4 
Analysis by RT-qPCR using GAPDH as the reference gene showed that ADAMTS-4 gene 
expression was significantly (P<0.05) elevated in the digital laminae of horses that developed 
OG1-lameness (n=6) after receiving starch gruel, compared to that in laminae of healthy control 
horses (n=8) (Fig 3.1).  There was also a trend towards elevated ADAMTS-4 gene expression in 
the digital laminae of horses at a developmental phase of laminitis corresponding to onset of 
fever (n=6), and at OG3 lameness (n=5).  However in these cases mean fold ADAMTS-4 induction 
values were lower than those in the laminae of horses with OG1-lameness, there was 
considerable sample variation, and mean values did not differ significantly from those in 
laminae of healthy horses.    
3.2.1.2  Versican 
Analysis by RT-qPCR using GAPDH as the reference gene, and primers specific for 
versican-G1, αGAG, βGAG and C terminal domains (Fig 3.2A), showed that expression of the 
gene encoding versican increased slightly at OG1-lameness (n=6) but declined substantially (2.5 
fold) and significantly (αGAG, P < 0.05; βGAG, P < 0.01; C terminal domain, P < 0.05) in the digital 
laminae of horses that developed OG3-lameness (n=5) compared to that in laminae of healthy 
horses (n=8).  RT-qPCR analyses performed using primers specific for the G1 domain sequence 
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of versican showed a similar although not significant reduction in its expression in laminae of 
horses with OG3-lameness compared to laminae from healthy horses (Fig 3.2A). 
3.2.1.3  Aggrecan 
Analysis by RT-qPCR using GAPDH as the reference gene showed that while mean fold 
expression of the gene encoding aggrecan was lower in laminae of horses with OG3 lameness 
(n=5) compared to that in laminae of healthy control horses (n=8), the values did not differ 
significantly (Fig 3.2B).     
3.2.2 Protein Expression 
3.2.2.1 ADAMTS-4 
Analyses by SDS-PAGE and Western blotting showed that two ADAMTS-4 polypeptides 
of 61 kDa and 51 kDa bearing the bearing the active site neopitope FASLSRFVET64 were 
significantly (≈2 fold, P ≤ 0.05 in each case) elevated in 0.5% NP-40 extracts of laminae of horses 
with OG1-lameness (n=6) relative to that in the laminae of control horses (n=8) (Fig 3.3).  The 51 
kDa form of ADAMTS-4 was more prevalent than the 61 kDa form in these and all other samples 
of laminae analyzed.  β actin, which is expected to remain constant in the tissue throughout 
development of laminitis, as is the case with β actin gene expression (data not shown), was used 
as a loading control to normalize values and a sample from the same protein extract was run in 
each blot (boxed in Fig 3.3) to facilitate comparisons between blots.  The 61 kDa and 51 kDa 
ADAMTS-4 expression values did not differ significantly between OG3 and control samples of 
laminae mirroring results of ADAMTS-4 gene expression analyses (Fig 3.1).   
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3.2.2.2 V0 and V1 Versican 
ADAMTS-4 cleaves V0 and V1 versican isoforms within the βGAG domain yielding 66 kDa 
and 109 kDa G1- βGAG fragments with a characteristic C terminal ADAMTS-4 DPEAAE cleavage 
neoepitope65.   Equine lamellar versican fragments bearing the DPEAAE neoepitope are fully 
extracted into 0.5% NP-40 (data not shown).  Comparative analysis of 0.5% NP-40 extracts of 
laminae from healthy horses and from horses with starch gruel-induced laminitis showed that 
the amount of the 66 kDa V0/V1 versican ADAMTS-4 cleavage fragment was significantly 
elevated (≈2.5 fold, P < 0.001) in the laminae of horses with OG3-lameness (n=5) relative to that 
in the laminae of control horses (n=8) (Fig 3.4).  The amount of the 109 kDa V0/V1 ADAMTS-4 
versican cleavage fragment was also raised (≈2 fold) in OG 3 relative to control laminae, 
although this increase was not statistically significant.  However, paired analyses of 109 kDa and 
66 kDa ADAMTS-4 cleavage fragments of V0/V1 versican showed these to be strongly, and 
highly significantly, positively correlated (Pearson’s r = 0.70, P < 0.001, r2 = 0.49) suggesting co-
ordinate generation.  Differential retention of the cleavage fragments in laminae, or selective 
further degradation in the laminae may account for unexplained variance in their respective 
abundance.   
3.2.2.3 V0 and V2 Versican 
V0 and V2 versican isoforms are constitutively cleaved by ADAMTS-4 yielding G1-αGAG 
fragments bearing a C terminal ADAMTS-4 NIVSFE cleavage neoepitope45.  NIVSFE positive 
polypeptides of 112 kDa, 68 kDa, 56 kDa, 34 kDa and 21 kDa were detected in extracts of 
laminae from healthy and laminitic horses (Fig 5).  Comparative analysis of 0.5% NP-40 extracts 
of laminae from healthy horses and from horses with starch gruel-induced laminitis, which 
contain all extractable NIVSFE-neoepitope bearing material, showed that the presence of the 
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112 kDa polypeptide was substantially and significantly reduced (≈8 fold, P < 0.001) in extracts 
of laminae from horses with OG1- (n=6) and OG3-lameness (n=5) compared to that in extracts of 
control laminae (n=8) (Fig5D) and this was paralleled by a decline (≈3 fold, P < 0.01) of the 56 
kDa NIVSFE positive fragment (Fig 5D).  The levels of the 112 kDa and 56 kDa fragments were 
strongly and significantly positively correlated (Pearson’s r = 0.76, P = 0.0001, r2 = 0.58), 
consistent with co-ordinate processing. 
  The reduction of the 112 kDa and 56 kDa V0/V2 versican fragments bearing the 
ADAMTS-4 cleavage neoepitope NIVSFE in laminitic laminae was accompanied by an increase of 
the 68 kDa (≈2.5 fold, P < 0.01), 34 kDa (≈3 fold, P < 0.001) and 21 kDa (≈9 fold, P < 0.01) 
polypeptides bearing the NIVSFE neoepitope.  These polypeptides showed moderate to strong 
positive paired correlations (n=19; 68 kDa vs 34 kDa - Pearson’s r = 0.47, P < 0.05; 68 kDa vs 21 
kDa - Pearson’s r = 0.79, p < 0.0001; 34 kDa vs 21 kDa - Pearson’s r = 0.73, P = 0.0004) consistent 
with a co-ordinate processing.    
3.2.2.4 Correlation Analysis of the 66 kDa DPEAAE-positive and 34 kDa and 21 kDa NIVSFE-
positive Versican Fragments 
Results presented in Figure 3.4 show that the concentration of the 66 kDa ADAMTS-4 
cleavage fragment of V0/V1 versican increases in laminitic laminae compared to that in healthy 
laminae.  Similarly, those in Figure 3.5 show that the levels of the 34 kDa and 21 kDa ADAMTS-4 
fragments also increase in laminitic laminae compared to healthy laminae.  A paired comparison 
of these data shows that there is a strong positive correlation between the concentrations of 
the 66 kDa V0/V1 versican fragment and the 34 kDa V0/V2 versican fragment (Pearson’s r = 
0.77, P < 0.0001, r2 = 0.59), and to a lesser extent between the 66 kDa and 21 kDa putative 
V0/V2 versican fragment (Pearson’s r = 0.53, P = 0.02, r2 = 0.28) consistent with co-ordinate 
processing of the V0/V1 and V0/V2 versican isoforms by ADAMTS-4.  Unexplained variance may 
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result from differential synthesis of V0, V1 and V2 versican isoforms relative to ADAMTS-4, or 
from differential fragment stability, or laminar retention in vivo. 
3.2.2.5 Aggrecan 
ADAMTS-4 cleavage fragments of aggrecan could be extracted from laminae in 4M 
guanidine hydrochloride but not 0.5% NP-40.  Extracted material was digested with 
chondroitinase ABC to remove chondroitin sulfate glycosaminoglycans.  Chondroitin sulfate 
glycosaminoglycan-free aggrecan fragments bearing the ARGSVI44 ADAMTS-4 cleavage 
neoepitope had MWs of, 250 kDa, 70 kDa and 50 kDa (Fig 3.6).  Relative amounts of the 250 kDa 
and 50 kDa polypeptides were similar in extracts of laminae from healthy horses (n=8) and 
laminae from horses with OG1- (n=6) or OG3-lameness (n=5).  The detection of the 70 kDa 
polypeptide decreased (≈2.5 fold, P < 0.001) in laminae from horses with OG3-lameness relative 
to that in extracts of normal laminae.  For these analyses a common sample was included in 
each gel (boxed in Fig 3.6A) and used to normalize data.  Actin was not detected in the 
preparations excluding its use as a loading control, but an equivalent amount of total protein 
was loaded in each lane. 
3.2.3 Protein Distribution 
3.2.3.1 Aggrecan and Versican 
Indirect immunofluorescence was performed on thin frozen sections of laminae from 
healthy horses and horses with starch gruel-induced laminitis to determine whether elevated 
ADAMTS-4 gene and protein expression affects the distribution of aggrecan or versican.  In 
these sections, nuclei were stained blue with DAPI, and aggrecan or versican were stained red 
using specific antibodies (Fig 3.7).  Images obtained from sections of laminae from a control 
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horse (Figs 3.7A and E), a horse with OG1-lameness (Fig 3.7B and F) and a horse with OG3-
lameness (Fig 3.7C and G) are presented, and are representative of those from animals in each 
group (control n=6; OG1 n=6; OG3 n=4).  Within each field, basal epithelial cells were examined 
for their mean intensity of red fluorescence and 60 fields were analyzed for each section, from 
each sample of laminae.  Results obtained from OG1 and OG3 samples were compared to those 
from control laminae and are presented in Figures 3.7D and H.  
Results presented in Figure 3.7 show that the distributions of aggrecan and versican are 
the same in the laminae of control and laminitic horses.  In all samples, aggrecan was present in 
the secondary epidermal laminae only and enriched in basal epithelial cells.  In all samples, 
versican was solely present in basal epithelial cells of the secondary epidermal laminae.  The 
intensity of aggrecan staining in basal epithelial cells of the secondary epidermal laminae was 
not affected by the development of laminitis as indicated by quantified specific staining (Fig 
3.7A-D).  In contrast, the level of versican was substantially (≈3 fold) and significantly lower in 
the laminae of horses with OG3-lameness than in the laminae of healthy horses (p<0.01) and 
those with OG1-lameness (p<0.05) (Fig 3.7E-H).  The level of versican in laminae of horses with 
OG1-lameness did not differ significantly from that in laminae of healthy control horses.   
3.2.3.2 Laminin and Actin 
Immunofluorescence analyses were also performed on thin frozen sections of laminae 
from healthy horses and horses with starch gruel-induced laminitis to examine the relationship 
of the basement membrane and basal epithelial cells.  Basement membrane laminin was stained 
red with a specific antibody, and cortical actin of basal epithelial cells was stained green with 
FITC-phalloidin.  Results from a control horse, a horse with OG1-lamness and a horse with OG3-
lameness are presented (Figure 3.8) and are representative of all horses in each group (control 
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n=6; OG1 n=6; OG3 n=4).  These results recapitulate histochemical observations reported by 
other investigators66, briefly basal epithelial cells in laminae of horses with OG3-lameness 
appear flattened and spread on the basement membrane compared to those of healthy horses.  
In addition, in some locations the basement membrane has pulled free of the tips of secondary 
epidermal laminae, and is also separated from basal epithelial cells in crypt regions of the 
secondary epidermal laminae (Fig 3.8C arrows).  
3.3 Discussion 
We show here that starch gruel induced laminitis causes an increase in ADAMTS-4 gene 
expression in the front hoof laminae of horses confirming earlier studies28.  In addition, we show 
that the increase in ADAMTS-4 gene expression is accompanied by an increase in ADAMTS-4 
activity, a decrease in versican gene expression that occurs between OG1- and OG3-lameness, 
increased concentrations of low molecular weight (MW) ADAMTS-4 cleavage fragments of 
V0/V1 and V0/V2 versican in the tissue, depletion of versican from basal epithelial cells and 
regional separation of basal epithelial cells from the basement membrane.  Although a direct 
pathophysiological consequence of versican loss cannot be established from the present study, 
this loss, together with changes in ADAMTS-4 and versican gene expression, indicates a global 
change in basal epithelial cell physiology which may contribute to detachment of the epithelial 
cells from the basement membrane and the development of severe lameness.  This conclusion is 
consistent with previous studies showing reduced desmosomal attachments of basal epithelial 
cells to adjacent basement membrane in laminitic tissue2.  
There was a moderate but significant positive correlation between expression of genes 
encoding versican and aggrecan in laminae.  However, analyses in other systems indicate that 
expression of these genes does not fit a straightforward program of co-regulation.  For example, 
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both aggrecan and versican gene expression are elevated in porcine chondrocytes subjected to 
microgravity67, whereas in ruptured Achilles tendons, aggrecan gene expression is elevated and 
that of versican depressed68.  Furthermore, exposure of equine articular cartilage to IL-1β elicits 
elevated versican gene expression but reduced aggrecan gene expression69.   
Both ADAMTS-4 and versican gene expression declined in the laminae of horses with OG3-
lameness relative to that in horses with OG1-lameness although to differing degrees.  
Nevertheless, there was a moderate positive correlation between expression of genes encoding 
ADAMTS-4 and versican, which is consistent with studies in other systems.  For example, 
incubation with TGFβ1 causes up-regulation of versican gene expression in human skin70 and 
bronchial epithelial cells71, as well as up-regulation of ADAMTS-4 gene expression in cultured 
human tendon cells72, and of both genes in prostatic stromal cells73.   A deeper analysis of 
signaling pathways that regulate expression of genes encoding ADAMTS-4, versican and 
aggrecan in laminar basal epithelium awaits the development of appropriate cell lines.     
 The elevated presence of ADAMTS-4 in laminae of horses with starch gruel induced 
laminitis was accompanied by a significantly elevated presence of V0/V1 and V0/V2 versican 
fragments bearing ADAMTS-4 cleavage neoepitopes.  Although aggrecan is a recognized 
substrate of ADAMTS-429 and is present together with ADAMTS-4 and versican in basal epithelial 
cells of the laminae60, the relative amount of aggrecan fragments bearing ADAMTS-4 cleavage 
neoepitopes did not increase in laminitic laminae.  The most likely interpretation of these 
surprising data is that aggrecan and versican are differentially cleaved by ADAMTS-4 in laminitic 
laminae.  Differential cleavage of versican versus aggrecan might result from differential 
specificity of the 51 kDa truncated form of ADAMTS-4, which is the predominant form in 
laminae, for these substrates, or from unequal partition of ADAMTS-4 into distinct aggrecan and 
versican rich compartments, or both.  In this regard, C terminal autoproteolytic truncation of 
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ADAMTS-4, which results in generation of the ~51 kDa form, has been shown to reduce the 
specificity of ADAMTS-4 for sulfated GAGs74 and to alter its substrate range42,75,76.   
    Levels of 68 kDa, 34 kDa and 21 kDa V0/V2 versican cleavage fragments bearing the 
ADAMTS-4 cleavage neoepitope NIVSFE were drastically increased in the laminae of horses with 
OG1- and OG3-lameness compared to laminae of healthy horses.  Cleavage of both V0 and V2 
versican isoforms by ADAMTS-4 occurs within the αGAG domain and is expected to yield a G1-
αGAG fragment that corresponds to the 68 kDa fragment reported here45,60.  Additional cleavage 
of this fragment is required to yield the 34 kDa and 21 kDa fragments.  It remains to be 
determined whether C terminal truncation of equine ADAMTS-4 endows it with this additional 
catalytic activity, or whether other proteases are involved.  It also remains to be determined 
whether the low MW V0/V1 and V0/V2 versican fragments, shown here to accumulate in 
laminitic laminae and to be soluble, are secreted and have biological activity that contributes to 
the pathophysiology of laminitis.   
Retention of aggrecan and loss of versican from basal epithelial cells during laminitis 
does not fit with the simple idea that cleavage of polysulfated proteoglycans by ADAMTS-4 
removes a protective gel layer thus increasing the vulnerability of basal epithelial cells to 
compression and concussion forces.  Of the two large polysulfated proteoglycans, aggrecan is 
the most heavily substituted with chondroitin sulfate29,30,31  and consequently would be expected 
to have the greater impact on retaining water in the tissue.  In addition to its role as a biological 
cushion, versican has also been shown to regulate a wide range of cell functions including 
proliferation, migration, and death.  Of particular interest is the ability of recombinant V1 
versican to induce mesenchymal to epithelial cell transition of the NIH3T3 fibroblast cell line and 
to regulate expression of cadherins and connexins increasing cell adhesion and communication 
through gap junctions63,77.  Also of interest is the ability of recombinant V2 versican to inhibit cell 
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proliferation.  If V1 and V2 versican isoforms exert these regulatory functions in basal epithelial 
cells of the equine digital laminae, their depletion through reduced gene expression and 
ADAMTS-4 cleavage, might lead to functional modification of the basal epithelial cells.  
Furthermore, differential depletion of V1 and V2 versican isoforms, which can be inferred from 
the greater accumulation in laminae of V0/V2 compared to V0/V1 versican ADAMTS-4 cleavage 
fragments, would be expected63,77,78  to favor an elevation in proliferation of the basal epithelial 
cells combined with some loss of phenotype.  
 Based on the above, we propose that versican plays a key role in regulating basal 
epithelial cell physiological properties in the equine digital laminae.  Further, we propose that its 
depletion through cleavage by ADAMTS-4 and down regulation of gene expression in laminitic 
laminae is responsible for the observed changes in the basal epithelial cells and their 
detachment from the basement membrane, thus, contributing to separation of the laminae at 
the epidermal-dermal junction. 
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3.4 Chapter 3 Figures 
 
 
Figure 3.1  
ADAMTS-4 Gene Expression in Healthy and Laminitic Laminae:  RNA was extracted from three 
separate sections of dorsal lamina from each horse and reverse transcribed into cDNA. 
Quantitative real-time PCR was performed in triplicate for each cDNA preparation using 
optimized gene-specific primers to analyze gene expression levels of ADAMTS-4 normalized to 
GAPDH in corresponding samples.  The study was repeated using different sections of dorsal 
laminae.  For each gene, primers were selected so that they do not amplify genomic DNA.  * P < 
0.05 compared with the control animals, determined from 95% confidence intervals of the 
treated samples by 1-way ANOVA.  Results are mean ± 1SD.  CON (n=8), DEV (n=6), OG1 (n=6), 
OG3 (n=5). 
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Figure 3.2  
Aggrecan and Versican Gene Expression in Healthy and Laminitic Laminae:  RNA was extracted 
from three separate sections of dorsal lamina from each horse and reverse transcribed into 
cDNA.  Quantitative real-time PCR was performed in triplicate for each cDNA preparation using 
optimized gene-specific primers to analyze gene expression levels of versican (A) and aggrecan 
(B) normalized to GAPDH in corresponding samples.  The study was repeated using different 
sections of dorsal laminae. * P < 0.05, **<0.01 compared with the control animals, determined 
from 95% confidence intervals of the treated samples. Results are mean ± 1SD.  CON (n=8), OG1 
(n=6), OG3 (n=5). 
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Figure 3.3  
 ADAMTS-4 Protein Expression in Healthy and Laminitic Laminae: Western blots of 0.5% NP-40 
extracts (30 μg protein/lane) from laminae of:  A) healthy horses (CON; n=8), B) horses with 
OG1-lameness (n=6) and C) horses with OG3- lameness (n=5).  Samples were subjected to SDS-
PAGE in 10% gels, polypeptides transferred to polyvinylidine fluoride membrane and blots 
probed using an antibody against neoepitope FASLSRFVET exposed on ADAMTS-4 catalytic 
domain after removal of the regulatory propeptide.  Blots were stripped and probed with an 
antibody specific for β-actin, which was used as a loading control.  The bands enclosed by the 
black box are from a common sample (from the OG1 group) that was run in all gels and used for 
normalizing experiment variation. D) The intensity of chemiluminescence was quantified and 
values were statistically analyzed. * P < 0.05 compared with the control, determined from 95% 
confidence intervals of the treated samples. 
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Figure 3.4 
 V0/V1 Versican Protein Expression in Healthy and Laminitic Laminae:  Western blots of 0.5% 
NP-40 extracts (30 μg protein/lane) from laminae of : A) healthy horses (CON; n=8), B) horses 
with OG1-lameness (n=6) and  C) horses with OG3-lameness (n=5). Samples were subjected to 
SDS-PAGE in 10% gels, polypeptides transferred to polyvinylidine fluoride membrane and the  
blots probed using antibodies to the neoepitope  DPEAAE of versican V0/V1 generated by 
ADAMTS 4.  β-actin was used as load control.  The bands enclosed by the black box represent a 
common sample (from the OG1 group) that was run in all gels and used for normalizing 
experiment variation. D) The intensity of chemiluminescence was quantified and values were 
statistically analyzed. *** P<0.001 compared with the control. 
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Figure 3.5 
 V0/V2 Versican Protein Expression in Healthy and Laminitic Laminae: Western blots of 0.5% 
NP-40 protein extracts (30 μg protein/lane) from laminae of:  A) healthy horses (CON; n=8), B) 
horses with OG1-lameness (n=6) and  C) horses with OG3-lameness (n=5).  Samples were 
subjected to SDS-PAGE in 10% gels, polypeptides transferred to polyvinylidine fluoride 
membrane and blots probed using antibodies to the neoepitope  NIVSFE of versican V0/V2 
generated by ADAMTS 4.   β-actin was used as load control. The bands enclosed by the black box 
represent a common sample (from the OG1 group) that was run in all gels and used for 
normalizing experiment variation. D) The intensity of chemiluminescence was quantified and 
values were statistically analyzed. ** P< 0.01, *** P<0.001 compared with the control, 
determined from 95% confidence intervals of the treated samples. 
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Figure 3.6  
Aggrecan Protein Expression in Healthy and Laminitic Laminae:  Western blots of 
hyaluronidase- and chondroitinase ABC- digested 4M guanidine hydrochloride extracts (30 μg 
protein/lane) from laminae of: A) healthy horses (CON; n=8), B) horses with OG1-lameness (n=6) 
and C) horses with OG3-lameness (n=5).  Samples were subjected to SDS-PAGE in 10% gels, 
polypeptides transferred to polyvinylidine fluoride membrane and blots probed using antibodies 
to the aggrecan neoepitope  ARGSVIL generated by ADAMTS 4. The bands enclosed by the black 
box represent a common sample (from the OG1 group) that was run in all gels and used for 
normalizing experiment variation. D) The intensity of chemiluminescence was quantified and 
values were statistically analyzed. *** P<0.001 compared with the control, determined from 
95% confidence intervals of the treated samples. 
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Figure 3.7 
Distribution of Aggrecan and Versican in Healthy and Laminitic Laminae:  Thin sections of 
frozen laminae from: (A,E) a representative healthy horse, (B,F) a representative horse with 
OG1-lameness, and (C,G) a representative horse with OG3-lameness were stained red with 
antibodies against (A-C) aggrecan and (E-G) versican. Autofluorescent laminae components 
(putatively collagen and keratin) fluoresce in green, nuclei are stained blue with DAPI.  Scale 
bars 50μm.  Average fluorescence was quantified and statistically analyzed using 2-way ANOVA 
and Duncan’s post test.  D) Quantification of aggrecan expression in sections from laminae of 
healthy horses (n=6) and horses with OG1 (n=6) and OG3 (n=4) lameness, H) quantification of 
versican in sections from laminae of healthy horses (n=8) and horses with OG1 (n=6) and OG3 
(n=4) lameness. ** p<0.01, *p<0.05. 
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Figure 3.8  
Histological Structure of Healthy and Laminitic Laminae:  Thin sections of laminae from: (A) a representative healthy horse, (B) a 
representative horse with OG1-lameness and (C) a representative horse with OG3-lameness were stained with an antibody against laminin 
(red) to visualize the basement membrane, and phalloidin-FITC to visualized intracellular cortical actin (green).  Nuclei stained in blue with 
DAPI. Scale bars 50μm. 
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CHAPTER 4 
 
IMPACT OF LAMINITIS ON THE CANONICAL WNT SIGNALING PATHWAY IN BASAL EPITHELIAL 
CELLS OF THE EQUINE DIGITAL LAMINAE 
4.1 Introduction 
Failure of the laminar epidermal:dermal junction in horses with starch-gruel induced 
laminitis, which is a model for natural disease6, is associated with physiological changes in 
laminar basal epithelial cells (LBEC).  These include a diminished number of hemidesmosomes 
per unit area of basement membrane2,51, expression of the stress protein calprotectin54, 
elevated gene and protein expression of A Disintegrin And Metalloproteinase with 
Thrombospondin Motifs-4 (ADAMTS-4)28 and depletion of intracellular versican by a 
combination of elevated ADAMTS-4 cleavage and suppressed versican gene expression79. 
Versican gene expression is linked to mesenchymal to epithelial transition in cell culture 
experiments and the proteoglycan induces mesenchymal to epithelial transition of metastatic 
tumor cells accelerating their proliferation80. Consequently, the depletion of versican from LBEC 
in laminitic horses may affect epithelial cell lineage commitment and associated functions that 
are critical to maintaining the laminar epidermal:dermal junction. Furthermore, rat and human 
versican gene expression can be induced by the β-catenin/TCF transcription complex81,82 and 
thus, is regulated by the canonical Wnt signaling pathway (reviewed in 83-85),  raising the possibility 
that suppressed versican gene expression in LBEC of horses presenting laminitis may result from 
perturbations in the canonical Wnt signaling pathway.   
The canonical Wnt signaling pathway is one of the fundamental pathways that control cell 
development, proliferation, differentiation, polarity and motility. The core activity of the 
pathway is regulation of the production and stability of β-catenin in the cell. This is important 
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because β-catenin mediates canonical Wnt signaling by binding to and activating members of 
the T cell factor (TCF) transcriptional factor family.  The canonical Wnt signaling pathway 
regulates expression of genes encoding versican36,81  and many other proteins.  Pathway 
components that elevate production and stability of β-catenin are called “positive regulators”. 
These are: (i) Wnt, named after Wingless in Drosophila and integration 1 in mouse breast 
tumors, which is a glycoprotein that activates the pathway,  (ii) its receptor, frizzled (FZD), (iii) its 
co-receptor, low density lipoprotein receptor related protein (LRP); (iv) disheveled (Dsh) which 
together with the Wnt/FZD/LRP complex forms a signalosome that inhibits glycogen synthase 
kinase 3β (GSK3β) thus stabilizing β-catenin by preventing its phosphorylation and therefore its 
ubiquitination and proteasomal degradation, (v) protein phosphatase 1 (PP1) and protein kinase 
B (Akt), which also prevent β-catenin phosphorylation, and (vi) TCF which in complex with 
transcriptional co-activator β-catenin induces target gene expression. Pathway components that 
diminish expression of β-catenin and elevate its degradation are called “negative regulators”. 
These are: (i) Dickkopf (DKK), which antagonizes Wnt signaling by binding the co-receptor LRP, 
(ii) components of the β-catenin degradation complex, namely, the scaffolding proteins Axin and 
adenomatous polyposis coli gene product (APC) which bind β-catenin, and (iii) casein kinase 1α 
(CK1α) and GSK3β which jointly phosphorylate bound β-catenin leading to its subsequent 
ubiquitination and proteasomal degradation.  
Here we determine: i) whether suppressed versican gene and protein expression which 
occurs in LBEC of laminitic horses83 is accompanied by changes in expression of E-cadherin and 
vimentin, and hence with a change in the lineage commitment of the cells, ii) whether positive 
and negative regulatory components of the canonical Wnt signaling pathway are expressed in 
LBEC and if so, how expression levels change during the development of laminitis, and iii) 
whether the development of laminitis is accompanied by changes in expression of components 
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of adherens junctions (E-cadherin and β-catenin) and hemidesmosomes (integrin α6 and 
integrin β4).  
4.2 Results 
4.2.1 Integrin β4, β-Catenin, and Vimentin Gene and Protein Expression 
In the laminae of both healthy horses and of horses with starch gruel-induced laminitis, 
expression of the hemidesmosome component integrin β4 is restricted to the single layer of 
basal epithelial cells of the secondary epidermal laminae (Fig 4.1A, B and C; stained red with 
specific antibody).  The protein is detected throughout the basal epithelial cell cytoplasm, and a 
portion is present at the cell margin adjacent to the basement membrane (Fig 4.1D, E and F; 
stained green with anti-pan-laminin), as indicated by co-localization (Fig 4.1G, H and I; stained 
yellow as a result of merged green and red stains at the integrin β4:laminin interface). The level 
of expression of the gene encoding integrin β4 is significantly reduced in laminae of horses 
presenting OG3 lameness compared to that in healthy horses (Fig 4.1J). In addition, there is a 
significant drop in integrin β4 protein concentration in extracts of laminae from horses 
presenting OG1 and OG3 lameness compared to those prepared from healthy horses (Fig 4.1K; 
Western blots shown in Fig 4.2, panel A).  In horses with starch-gruel induced laminitis, 
suppressed integrin β4 gene and protein expression (Fig 4.1J and K) is accompanied by 
separation of the basement membrane and basal epithelial cells in focal areas proximal to the 
primary epidermal laminae (Fig 4.1I; indicated by white ovals) a condition that is not observed in 
sections of laminae from healthy horses or horses presenting OG1 lameness.    
Reduced expression of integrin β4 in laminitic laminae is accompanied by reduced gene 
and protein expression of the adherens junction and canonical Wnt signaling pathway 
component β-catenin (Fig 4.3A and 3B; Western blots shown in Fig 4.2, panel B). In addition, the 
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level of expression of the gene encoding β-catenin in laminae correlates strongly and positively 
with that of the gene encoding integrin β4 (Fig 4.3C Pearson’s r = 0.74; p=0.0003) consistent 
with the possibility that expression of these genes is co-regulated.  Like integrin β4, β-catenin is 
highly expressed in LBEC of healthy and laminitic horses (Fig 4.3 D-G; stained red with specific 
antibody), where it is richly present around cell margins (Fig 4.3E).  E-cadherin is also highly 
expressed in these cells (Fig 4.3H-J; stained green with specific antibody) and for the most part 
co-localizes with β-catenin (Fig 4.3K-M; stained yellow as a result of merged green and red 
stains) to which it is tethered in adherens junctions.   
Gene (at OG1) and protein (at OG3) expression of the type III intermediate filament 
protein vimentin,  which is a marker of mesenchymal cells86, is significantly elevated in the 
laminae of laminitic horses compared to laminae of healthy horses (Figs 4.4G and H; Western 
blots shown in Fig 4.2, panel C).  Vimentin protein (stained red with specific antibody) is 
expressed by cells of the primary and secondary dermal laminae of healthy and laminitic horses 
but not by cells of the epidermal laminae (Figs 4.4A – F).  LBEC from healthy horses (Fig 4.4A and 
D) and from horses presenting OG1 (Fig 4.4B and E) or OG3 (Fig 4.4C and F) lameness have a 
well-developed cortical actin cytoskeleton which stains green with phalloidin-FITC and do not 
express vimentin.  Hence, elevated vimentin gene and protein expression in laminae of laminitic 
horses (Figs 4.4G and H) is restricted to cells of the dermal connective tissue. 
4.2.2 Expression of Canonical Wnt Signaling Pathway Components 
Levels of β-catenin protein expression are regulated by the canonical Wnt signaling 
pathway.  Levels of β-catenin gene expression may also be regulated, directly and indirectly, by 
the canonical Wnt signaling pathway 87. Consistent with suppressed β-catenin gene and protein 
expression in laminitic laminae, expression of genes encoding positive canonical Wnt signaling 
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pathway regulators, namely Wnt4, FZD4, LRP6, Dsh and PP1, is also suppressed (Fig 4.5A-E). 
Furthermore, immunofluorescence staining shows that Wnt4 is mainly expressed in the basal 
and supra-basal epithelial cells of the secondary epidermal lamellae of healthy and laminitic 
horses (Fig 4.6A, B, C; stained red with specific antibody), while FZD4 is mainly expressed in LBEC 
(Fig 4.6D, E, F; stained red with specific antibody).  
Whereas expression of genes encoding positive regulators of the canonical Wnt 
signaling pathway is suppressed in the laminae of laminitic horses (Fig 4.7A-E), expression of 
genes encoding components of the β-catenin degradation complex (negative regulators of the 
canonical Wnt signaling pathway) is either transitorily elevated, namely, Axin 1 and CK1α (Fig 
4.5F and H), suppressed, namely, APC (Fig 4.5G), or unaltered, namely, GSK3β (Fig 4.5I).  
Although the level of GSK3β gene expression is unaltered in the laminae of laminitic horses 
relative to that in the laminae of healthy horses, the level of GSK3β protein increases in laminitic 
laminae (Fig 4.7A), that of serine-9-phospho-GSK3β (p-GSK3β) is unchanged (Fig 4.7B), and ratio 
of p-GSK3β to total GSK3β decreases (Fig 4.7C; Western blots shown in Fig 4.2, panel D and E). 
Expression of the gene encoding Akt2, which is known to phosphorylate GSK3β and accelerate 
its degradation88, was also reduced in laminae of laminitic compared to healthy horses (Fig 
4.7D).    
Finally, expression of the gene encoding TCF4, which in complex with transcriptional co-
activator β-catenin induces target gene expression in the canonical Wnt signaling pathway77, is 
suppressed in laminitic laminae (Fig 4.8A). Furthermore, comparative analyses of gene 
expression in laminae of all control, OG1 and OG3 animals show there are strong positive 
correlations between the expression of genes encoding β-catenin and TCF4 and those encoding 
some positive and negative regulators of the canonical Wnt signaling pathway (Fig 4.8B) 
consistent with feed forward regulatory loops.  Most notable among these are TCF4 and the 
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positive pathway regulator LRP-6 (Pearson’s r = 0.8580, P<0.0001), and TCF4 and the negative 
regulators GSK3β (Pearson’s r = 0.7800, P<0.0001) and APC (Pearson’s r = 0.8174, P<0.0001).   
A strong positive correlation was also observed between the gene encoding TCF4 and that 
encoding versican (Pearson’s r = 0.89, P < 0.0001), and a moderate positive correlation between 
the gene encoding β-catenin and that encoding versican (Pearson’s r = 0.64, P = 0.003). In 
addition, there was a strong positive correlation between expression of the gene encoding TCF4 
and that encoding integrin β4 (Pearson’s r = 0.69, P = 0.001), and between the gene encoding 
and β-catenin and integrin β4 (Pearson’s r = 0.74, P = 0.0003). 
4.3 Discussion 
Studies reported above show that genes and proteins encoding multiple positive regulators 
of the Canonical Wnt Signaling Pathway were decreased in the laminae of horses affected by 
laminitis. In addition, many of the known negative regulators of the wnt pathway were 
increased in the same conditions suggesting that the wnt signaling pathway is negatively 
regulated during the progression of laminitis. This possibility is further supported by evidence 
that Versican, one of the known targets of the Wnt pathway81,82,  is significantly decreased 
during laminitis progression79.  In addition, expression of versican in laminae correlated 
positively with expression of genes encoding β-catenin (Pearson’s r = 0.64) and TCF4 (Pearson’s r 
= 0.89, p < 0.0001) which jointly constitute the co-transcriptional activator that regulates gene 
expression in the canonical Wnt signaling pathway. Determination of the importance of wnt 
signaling in the progression of laminitis will require additional studies that could involve the use 
of activators of the pathway, for example GSK3 inhibitors, to see if those can delay or prevent 
the progression of the disease as discussed below. 
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Versican gene and protein expression is associated with mesenchymal-to-epithelial cell 
transition in transfected NIH 3T3 cells63,77, and versican in extracellular matrix has been 
demonstrated to promote mesenchymal-to-epithelial transition of metastatic tumor cells89. In 
addition, during development of the vertebrate heart tube, ADAMTS-mediated cleavage of 
versican is associated with the formation of endocardial cushion mesenchyme90.  However, in 
spite of versican depletion from LBEC of laminitic horses79, the cells did not lose their epithelial 
phenotype or acquire characteristics of mesenchymal cells evidenced by the sustained 
expression of the epithelial cell marker E-cadherin and lack of expression of the mesenchymal 
cell marker vimentin. This is perhaps not surprising because epithelial-to-mesenchymal 
transition is dependent on the canonical Wnt signaling pathway91, which the data presented 
here suggest is suppressed in LBEC of laminitic horses. 
Although vimentin gene and protein were not expressed in LBEC of healthy or laminitic 
horses, vimentin was strongly expressed by connective tissue cells in the dermal laminae and 
expression was elevated in laminitic horses. Vimentin is a type III intermediate filament protein 
present in mesenchymal cells.  In addition to expression by cells undergoing epithelial to 
mesenchymal transition, it is constitutively expressed by resting fibroblasts and expression is 
elevated in stimulated92 and stressed cells93.  Its elevated expression in laminar dermal cells of 
laminitic horses is consistent with the previously shown inflammatory response occurring in this 
tissue at the onset of lameness54,87, which may elicit a stress/repair response in dermal 
fibroblasts. 
Despite the absence of epithelial-to-mesenchymal transition in LBEC of laminitic horses, 
there was evidence of impaired function. The diminished presence of positive regulators and 
elevated presence of negative regulators of the canonical Wnt signaling pathway in LBEC of 
laminitic horses correlated with diminished expression of β-catenin and integrin β4, which are 
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components of adherens junctions and hemidesmosomes respectively94,96 and are thus required 
for basal epithelial cell:cell and cell:basement membrane attachment.  Based on these 
observations, we propose that suppression of the canonical Wnt signaling pathway in LBEC and 
accompanying reduced integrin β4 gene and protein expression, is a contributing factor to the 
reduction in number of hemidesmosomes per unit area of LBEC/basement membrane interface 
reported in laminitis2.   
Although the expression of genes encoding β catenin and integrin β4 was strongly positively 
correlated in equine laminae (Pearson’s r = 0.74, p = 0.0003), direct regulation of integrin β4 
gene expression by the canonical Wnt signaling pathway was not demonstrated, and there is no 
report of this in the literature. In contrast, cross talk has been reported between the canonical 
Wnt signaling pathway and other signaling pathways96,97 and multiple lines of evidence exist that 
the Wnt pathway is regulated by integrins. For example, beta1 integrin can activate Wnt via the 
integrin linked kinase (ILK)98 and the adaptor protein growth factor receptor-bound-2 (Grb-2) 
has been shown to be recruited by integrin β4 as a result of its interaction with collagen in the 
extracellular matrix99 and to enhance β catenin-dependent Wnt signaling100. Additional studies 
are required to establish whether diminished integrin β4-dependent signaling causes down 
regulation of the canonical Wnt signaling pathway in laminae of laminitic horses, or vice versa, 
or whether both pathways are down regulated by laminitis-associated changes in other signal 
pathways. 
Suppressed canonical Wnt signaling may not solely be a feature of starch gruel-induced 
laminitis. In support of this possibility, it has been shown that the number of hemidesmosomes 
per micrometer of basement membrane is decreased in ponies with insulin-induced laminitis101, 
as it is in horses with oligofructose-induced laminitis2.  In addition, preliminary proteomic 
studies show that the level of β-catenin is lower in extracts of laminae from horses with 
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hyperinsulinemia-induced laminitis compared to extracts of laminae from healthy horses (Dr. 
Hannah Galantino-Homer, Personal Communication).  It is important to point out that the 
diminished presence of β-catenin in extracts of laminae from hyperinsulinemic animals does not 
necessarily mean that the canonical Wnt signaling pathway is suppressed in the laminae of 
these animals; given that β-catenin is sequestered by E-cadherin102, a reduction in β-catenin 
expression could be compensated by a matched reduction in E-cadherin expression. Thus, a 
detailed analysis of canonical Wnt signaling pathway components and regulators is warranted in 
laminae of horses presenting laminitis of diverse etiology.  It is worthy of note that cross talk 
between insulin/insulin like growth factor receptor signaling and the Wnt signaling pathway has 
been established103 although non-canonical Wnt signaling rather than the canonical pathway is 
linked to insulin resistance104,105. 
If suppression of the canonical Wnt signaling pathway in LBEC is a feature of laminitis of 
diverse etiology, pathway agonists may help to ameliorate laminar pathology.  In this regard, 
expression of genes encoding the adherens junction component E-cadherin and the 
hemidesmosome component integrin α6 was not suppressed in horses with starch gruel-
induced laminitis (Fig 4.9) and E-cadherin protein expression was not suppressed (Fig 4.2, panel 
F) supporting the possibility that adherens junctions and hemidesmosomes might be restored by 
sustaining β-catenin expression, e.g., through administration of agents that inhibit GSK3β106.  
This attractive possibility is contradicted by studies showing that protein expression of integrin 
α6 and anchoring filaments BP180 and laminin 5 is reduced in horses with oligofructose-induced 
laminitis based on immunofluorescence staining 107, consistent with complex disruption of the 
hemidesmosome.  However, it is possible that the reduced expression of integrin β4 affects 
expression of other hemidesmosome components. Indeed, murine keratinocytes that lack 
integrin β4 also lack other hemidesmosome components 108.  Clearly if suppression of the 
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canonical Wnt signaling pathway proves to be a feature of laminitis irrespective of etiology, it 
will be important to determine which, and to what extent, hemidesmosome, adherens junction 
and desmosome components are affected in LBEC of the laminitic animals and to determine the 
impact of sustaining β-catenin expression on the attachment of the basal epithelial cells to each 
other and to the basement membrane. Similarly, it will be important to identify the 
physiological process that results in diminished expression of β-catenin in laminae of laminitic 
horses.  
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4.4 Chapter 4 Figures 
 
 
 
Figure 4.1  
Distribution and Expression of Integrin β4 in Healthy and Laminitic Laminae: A-I - 10μm 
sections of frozen laminae from:  A, D, G - a representative (n=3) healthy horse (CON) (D – LBEC 
= laminar basal epithelial cell, BM = basement membrane, SEL = secondary epidermal laminae, 
PEL = primary epidermal laminae, SDL = secondary dermal laminae); B, E, H - a representative 
(n=4) horse with OG1-lameness (OG1); and C, F, I - a representative (n=3) horse with OG3-
lameness (OG3) were stained with antibodies against integrin β4 (A,B,C - red) and  against 
laminin (D,E,F green). Red and Green fluorescence merge in yellow (G, H, I). Nuclei are stained 
blue with DAPI. White circles indicate areas of dissociation between basal epithelial cells and 
basement membrane laminin. Scale bars 50µm.  J - Quantitation of integrin β4 and gene 
expression relative to the gene expression of GapDH. K - Quantitation of integrin β4 protein 
expression relative to β actin.  Horizontal lines indicate mean ± standard error of mean of n=8 
CON, n=6 OG1 and n=5 OG3, ** = p<0.01, *** = p<0.001 as calculated by one-way ANOVA. 
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Figure 4.2  
Wnt Signaling Pathway Protein Expression in Healthy and Laminitic Laminae: Western blots of 
0.5% NP-40 extracts (30 μg protein/lane) from laminae of healthy horses (CON; n=8), horses 
with OG1-lameness (n=6) and horses with OG3-lameness (n=5) showing expression of: A. 
integrin β4; B. β-catenin; C. vimentin; D. GSK 3β; E. serine-9-phospho GSK3β (pGSK 3β); F. E- 
cadherin; β actin was used as load control.  The bands enclosed by the black box represent a 
common sample (from the OG1 group) that was run in all gels and used for normalizing 
experiment variation. The intensity of chemiluminescence was quantified and values were 
statistically analyzed shown in Fig 1K, Fig2B, Fig3H, Fig5A, B and FigS4A respectively. 
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Figure 4.3 
Distribution of β-catenin and E-cadherin in Healthy and Laminitic Laminae: A - Quantitation of 
β-catenin gene expression relative to the gene expression of GapDH. B - Quantitation of β-
catenin protein expression relative to the protein expression of β actin.  Horizontal lines indicate 
mean ± standard error of mean * = p<0.05 as calculated by one-way ANOVA. C - Correlation 
between expression of genes encoding β-catenin and integrin β4: Pearson r= 0.7418, p=0.0003. 
Solid line represents the predicted positive correlation by linear regression; Area within the 
dotted lines represents 95% confidence. n=8 CON, n=6 OG1, and n=5 OG3. D-M (20X objective) - 
10μm sections of frozen laminae from:  D, H, K - a representative (n=3) healthy horse (CON) (D – 
LBEC = laminar basal epithelial cell, SBEC= supra-basal epithelial cell) ; F, I, L - a representative 
(n=4) horse with OG1-lameness (OG1) and G, J, M - a representative (n=3) horse with OG3-
lameness (OG3) were stained with antibodies against β-catenin (D, F, G- red) and E-cadherin (H, 
I, J - green). Red and Green fluorescence merge in yellow (K, L, M). Nuclei are stained blue with 
DAPI. Scale bars 50µm. E (63X objective) – β-catenin stained in red, nuclei stained blue. 
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Figure 4.4 
Distribution and Expression of Vimentin in Healthy and Laminitic Laminae: A, B, C (20X 
objective), D, E, F (63X objective) - 10μm sections of frozen laminae from a representative (n=3) 
healthy horse (A,D), a representative (n=4) horse with OG1-lameness (B,E) and a representative 
(n=3) horse with OG3-lameness (C,F) were stained with antibodies against vimentin (red) and 
with phalloidin-FITC (green). Nuclei are stained blue with DAPI. Scale bars 50µm. G - 
Quantitation of vimentin gene expression relative to the gene expression of GapDH. H - 
Quantitation of vimentin protein expression relative to the protein expression of β actin.  
Horizontal lines indicate mean ± standard error of mean * = p<0.05 as calculated by one-way 
ANOVA. n=8 CON, n=6 OG1, and n=5 OG3. 
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Figure 4.5  
Gene expression of Wnt signaling pathway regulators:  Expression of genes encoding A - Wnt4, 
B - FZD4, C - LRP6, D - Dsh, E - PP1, F - Axin1, G - APC, H - CKIα, I - GSK3β relative to the gene 
expression of GapDH. Horizontal lines indicate mean ± standard error of mean of n=8 CON, n=6 
OG1, and n=5 OG3, animals.  * = p<0.05, ** = p<0.01, as calculated by one-way ANOVA. 
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Figure 4.6 
Distribution of Wnt4 and FZD4 in Healthy and Laminitic Laminae: 10μm sections of frozen 
laminae from: A, D - a representative (n=3) healthy horse (CON), B, E - a representative (n=4) 
horse with OG1-lameness (OG1) and C, F - a representative (n=3) horse with OG3-lameness 
(OG3) were stained red with antibodies against Wnt4 (A, B, C) and FZD4 (D, E, F) (panel F–PEL = 
primary epidermal laminae). Nuclei are stained blue with DAPI. Images were taken with a 20x 
objective. Scale bars 50µm. 
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Figure 4.7 
Protein Expression and Phosphorylation of GSK3β: A Total GSK3βprotein expression relative to 
β actin; B – Phosphorylated S9 GSK3βprotein (p-GSK3β) expression relative to β actin; C -Ratio of 
p-GSK3β to total GSK3β; D - Akt2 gene expression relative to GapDH. Horizontal lines indicate 
mean ± standard error of mean of n=8 CON, n=6 OG1, and n=5 OG3 animals. * = p<0.05, ** = 
p<0.01as calculated by one-way ANOVA. 
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Figure 4.8  
TCF4 Gene Expression and Correlation Summary: A - Gene expression of TCF4 relative to the 
gene expression of GapDH. Horizontal lines indicate mean ± standard error of mean of n=8 CON, 
n=6 OG1, and n=5 OG3 animals. B - Summary of correlation between expression of indicated 
genes. * = p<0.05, ** = p<0.01, *** = p<0.001 as calculated by one-way ANOVA. 
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Figure 4.9 
E-cadherin Protein Expression and Integrin α6 Gene Expression: A - Protein expression of E-
cadherin relative to the protein expression of β actin. B - Gene expression of integrin α6 relative 
to the gene expression of GapDH. Horizontal lines indicate mean ± standard error of mean of 
n=8 CON, n=6 OG1, and n=5 OG3 animals.  * = p<0.05 as calculated by one-way ANOVA. 
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CHAPTER 5 
 
EXPRESSION AND ACTIVITY OF COLLAGENASES IN THE DIGITAL LAMINAE OF HORSES WITH 
CARBOHYDRATE-INDUCED ACUTE LAMINITIS 
 
5.1   Introduction 
Loss of laminar structure during laminitis involves physiologic reprogramming of the 
basal epithelial cells by elevated expression of ADAMTS-479, depletion of versican79, suppressed 
expression of canonical Wnt signaling components109 and depletion of hemidesmosomes 
resulting in impaired basement membrane attachment2.  The latter is thought to involve 
degradation of ECM components by MMPs55,107,110.  MMPs have been a focus of interest in 
laminar pathophysiology for over a decade following: i) detection of gelatinases (MMP-2 and 
MMP-9) in the digital laminae of healthy horses111,  ii) elevated levels of MMP-2 and MMP-9 in 
explant medium from cultured laminae of laminitic compared to healthy horses112, iii) elevated 
levels of pro-MMP-9 in the serum of horses with carbohydrate -induced laminitis compared to 
healthy horses111, iv) histological evidence of extracellular matrix degradation in the laminae of 
horses with carbohydrate-induced laminitis110, and v) elevated levels of collagen IV fragments in 
the serum of horses with natural acquired laminitis compared to healthy horses113. More recent 
studies show that pro-MMP-9, but not regulatory propeptide-free MMP-9, is significantly 
elevated in the laminae of horses with black walnut extract induced laminitis56 as a result of 
neutrophil influx to the tissue. Pro-MMP-9 is also significantly elevated in the laminae of horses 
with carbohydrate overload-induced and naturally acquired laminitis, where it correlates with 
expression of myeloperoxidase and hence with inflammatory leukocytes. However, as in horses 
with BWE-induced laminitis, the pro-MMP-9 is not processed to active enzyme in either 
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condition53.  Because of the retained regulatory pro-peptide, which masks the catalytic site, pro-
MMP-9 is not catalytically active and hence is unlikely to contribute to degradation of the 
laminar ECM. Indeed, since the regulatory propeptide of pro-MMP-9 is removed by proteases in 
the ECM and is not removed intracellularly114, the MMP may not be secreted by inflammatory 
leukocytes despite their presence in the laminae of horses presenting laminitis.  
In contrast to MMP-9, both pro-MMP-2 and MMP-2 are significantly elevated in the 
digital laminae of horses presenting OG3 lameness after induction with carbohydrate overload  
compared to laminae of healthy horses. However, individual variation in laminar MMP-2 levels 
raise concerns regarding a correlation between MMP-2 protein expression and lameness. Thus, 
some severely lame horses have high levels of MMP-2 in extracts of their digital laminae, while 
others have little or no MMP-253. Furthermore, few horses that express OG1 lameness after 
carbohydrate-induction have MMP-2 in laminar extracts and these only at very low 
concentrations (Black laboratory, unpublished). Importantly, sections of laminae from severely 
lame horses do not differ from those of healthy horses with respect to levels of in situ gelatinase 
activity111 indicating a lack of accumulation in the laminitic tissue of MMP-2 that is free of bound 
tissue inhibitors of metalloproteinase (TIMP). These studies do not exclude a role for MMP-2 in 
laminar remodeling but open the possibility that MMPs in addition to the gelatinases may 
contribute to loss of lamellar function.  
Here we screen several candidate MMPs in extracts of laminae from healthy horses and 
horses with carbohydrate overload-induced laminitis to identify those that may contribute to 
laminar pathology. We report on two, MMP-1 and MMP-13, that are significantly elevated in the 
laminae of horses presenting acute laminitis compared to those of healthy horses, and map 
laminitis-associated changes in the distribution of some of their known substrates.  
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5.2 Results 
The expression of genes encoding MMP-1, -3, -13, -14, -15 and -16 was analyzed by qRT-PCR 
using primers described in Table 1; gene expression was detected in all cases in the laminae of 
healthy (Figure 5.1) and laminitic horses (not shown).  However, expression of genes encoding 
only two of the MMPs was found to be significantly upregulated in laminae of laminitic horses 
relative to their expression in laminae of healthy horses, namely MMP-1 (Figure 5.2A) and MMP-
13 (Figure 5.2B).  
To confirm that elevations in MMP-1 and MMP-13 gene expression correspond to elevations 
in protein expression, extracts of lamellar tissue were subjected to SDS-PAGE and Western 
blotting.  MMP-1 in extracts of laminae from healthy and laminitic horses resolved as a single 
polypeptide of 52 kDa corresponding to non-glycosylated pro-MMP-1115,116  and its expression 
was elevated in the laminae of horses presenting OG3 lameness but not OG1 lameness 
compared to that in laminae of healthy horses (Figure 5.3A). Pro-peptide free MMP-1 was not 
detected in any laminar extract. MMP-13 resolved as polypeptides of 61 kDa and 48 kDa 
corresponding respectively to pro-MMP-13 (61 kDa) and MMP-13 (pro-peptide free as active 
form)114,115  in extracts of laminae from healthy and laminitic horses (Fig 5.3B). Both pro-MMP-13 
and active MMP-13 were elevated in the laminae of horses expressing OG3, but not OG1 
lameness relative to laminae of healthy horses (Fig 5.3B).   MMP-13 was further localized in 
frozen laminar sections to the basal epithelium of the secondary epidermal lamellae, and 
localization was not changed over the course of disease development (Fig 5.4 A-C).  The 
metalloproteinase has wide substrate specificity, degrading types I, III and IV collagen, 
fibronectin and several other ECM components117. Type I collagen was distributed throughout 
the secondary dermal laminae (SDL) of healthy horses (Fig 5.4D control) and horses presenting 
OG1 lameness (Fig 5.4E, OG1), but dispersed to the edges of the SDL in horses presenting OG3 
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lameness (Fig 5.4F, OG3) leaving the appearance of multifocal gaps in the ECM. Fibronectin was 
also widely distributed throughout the SDL in laminae of healthy horses (Fig 3G) and horses 
presenting OG1 lameness (Fig 5.4H), but dispersed to the edges in some regions of SDL in horses 
presenting OG3 lameness, (Fig 5.4I) leaving the appearance of multifocal gaps in the ECM.  The 
specificity of antibodies used for these stains was confirmed by dot blotting (Figure 5.5).    
To further characterize the multifocal gaps that appear in the dermal ECM of horses 
presenting OG3 lameness, laminae from healthy and laminitic horses were stained with 
antibodies specific for chondroitin sulfate and keratan sulfate glycosaminoglycans. These stains 
revealed laminitis associated dispersion of the glycosaminoglycans to the edges of the SDL in 
horses presenting OG3 lameness (Fig 5.6 A-F) similar to that observed for collagen I and 
fibronectin.  Specificity of these stains were again confirmed by dot blotting (Fig 5.6G).   In 
addition, staining with hematoxylin and eosin showed that cells of the SDL are cocooned in an 
amorphous ECM that completely fills the SDL in healthy horses (Fig 5.7 panels A and D), and in 
horses presenting OG1 lameness (Fig 5.7 Panels B and E), but which is disrupted and absent 
from regions of the SDL neighboring the primary epidermal laminae in horses presenting OG3 
lameness (Figures 5.7 C and F).  
5.3 Discussion 
MMPs are a family of zinc-dependent endopeptidases capable of degrading essentially all 
components of the ECM. They are required for physiological remodeling of the ECM in tissue 
morphogenesis, growth and repair114. MMPs are dysregulated in pathological conditions such as 
rheumatoid arthritis, osteoarthritis and autoimmune blistering disorders of the skin114,118,119  and 
cause pathology by excessive degradation of the ECM in these conditions. We show here that 
healthy horses constitutively express genes encoding MMP-1, -3, -13, -14, -15 and -16 consistent 
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with on-going dynamic remodeling of the laminae, but expression of genes encoding MMP-1 
and -13 is selectively upregulated in the laminae of horses with starch-induced acute laminitis, 
consistent with a contribution of the MMP to laminitis associated pathology. Upregulation of 
MMP-1 gene expression occurred in the laminae of horses presenting OG1 and OG3 lameness, 
whereas upregulation of MMP-13 gene expression was detected only in horses presenting OG3 
lameness. Despite its upregulated expression MMP-1 is unlikely to contribute to pathologic 
laminar remodeling because only putatively non-glycosylated 52kDa pro-MMP-1114,115  was 
detected in extracts of laminae. In contrast, both pro- (61 kDa) and active (propeptide-free; 48 
kDa) forms  of MMP13114,115  were significantly increased in the laminae of horses presenting 
OG3 lameness relative to that in laminae of healthy horses, raising the possibility that MMP-13 
contributes to laminar pathology. 
MMP-1 and MMP-13 are known to be produced by activated fibroblasts, epithelial cells and 
inflammatory leukocytes in other systems114. In the case of the equine digital laminae, 
immunofluorescence analyses showed that MMP-13 localizes to the basal epithelial cells which 
line the junction between the epidermal and dermal laminae and which abut the SDL. Lack of an 
appropriate specific antibody precluded immune-localization of MMP-1 in laminae, but expression 
of the gene encoding MMP-1 has been localized to laminar basal epithelial cells by laser capture 
microscopy and qRT-PCR analysis (Belknap, personal communication). Dysregulation of MMP-1 
and MMP-13 therefore joins that of ADAMTS-479 as indicators of profound physiological stress in 
laminar basal epithelial cells associated with the development of laminitis.  
Expression and activation of MMPs are tightly controlled on several levels including 
regulation of transcription, enzymatic mediated cleavage of pro-peptide and inhibition by 
protease inhibitors. It has been shown that transcription factor Fos/Jun and AP-1mediate 
enhanced expression of MMP-1, MMP-13 and ADAMTS-4 in response to inflammatory factors 
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such as interleukin-1 and tumor necrosis factor alpha54,120 consistent with an inflammatory 
component of laminitis121,122. However, while laminar inflammation and elevated ADAMTS-479 
gene expression is detected as early as the developmental (fever) stage of starch-induced 
laminitis, elevated laminar MMP-1 gene expression is first detected at OG1 lameness, while that 
of MMP-13 gene expression becomes elevated at some (as yet unmapped) period between OG1 
and OG3 lameness. Thus, the relationship between MMP-13 expression and laminar 
inflammation is obscure.    
MMP-13, also named collagenase-3, cleaves the triple helix of Type I, III and IV collagens, 
and also cleaves fibronectin, and laminin. Cleaved triple helical collagen denatures 
spontaneously at 37 °C into gelatin and is further degraded by MMP-2 and MMP-9114,115, the 
former of which is significantly elevated in the laminae of horses presenting OG3 lameness 
compared to those of healthy horses53. Fibronectin also plays a critical role in maintaining the 
integrity of the ECM because it binds both to the extracellular domain of membrane spanning 
integrins and to ECM components such as collagen and heparin sulfate proteoglycans, mediating 
attachment of cells to the ECM and ECM components to each other123.  Thus, elevated presence 
of processed MMP-13 if accompanied by elevated substrate cleavage, would compromise the 
integrity of the dermal ECM and its capacity to accommodate ambient biomechanical forces 
without tearing.  Consistent with this possibility, we report here that Type I collagen and 
fibronectin are substantially redistributed in the secondary dermal laminae of horses presenting 
OG3 lameness compared to those of healthy horses as are other ECM components, giving the 
appearance of multifocal gaps or tears in the ECM.  However, although we favor the possibility 
that MMP-13 contributes to the development of laminar pathology, correlated events are not 
necessarily causally related. Consequently, the extent to which substrate degradation by MMP-
13 contributes to the development of multifocal gaps in the dermal ECM remains to be 
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determined, which will require selective in situ inhibition of the MMP in horses with acute 
starch-induced laminitis.      
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5.4 Chapter 5 Figures 
 
 
 
Figure 5.1 
Validation of qRT-PCR Primers:   Lanes 1) DNA ladder, 2) MMP-1, 3) MMP-13, 4) MMP-14, 5) 
MMP-16, 6) MMP-3, 7) MMP-15, 8) GapDH housekeeping gene, and 9) blank control. 
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Figure 5.2 
Gene Expression of MMPs 1 and 13 in Acute Laminitis: qRT-PCR analysis of lamellar gene 
expression of A) MMP-1 and B) MMP-13 in control (n=8), developmental (n=6), OG1 (n=6), and 
OG3 (n=5) animals. * indicates p<0.05, ** indicates p<0.01. 
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Figure 5.3 
 Increase in protein expression of MMP-1 and MMP-13: Western blot analysis of protein 
expression of MMP-1 A) and MMp-13 B) in lamellar extracts from control (n=8), OG1 (n=6), and 
OG3 (n=5) animals.   Box signifies common sample run in all three gels to normalize 
experimental variation between gels.  52kDa band corresponds to the pro-form of MMP-1 and 
61kDa band corresponds to the pro-form of MMP-13 while 48kDa band corresponds to the 
active form of MMP-13..* indicates p<0.05, ** indicates p<0.01. 
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Figure 5.4 
Distribution of MMP-13 and its Substrates in the Secondary Dermal Lamellae: 
Immunofluorescent staining (red) of MMP13 (A-C),  collagen type I (D-F) and fibronectin (G-I) in 
tissue sections from control (n=6), OG1 (n=6), and OG3 (n=4) animals. Representative images 
shown. Autofluorescent collagen shown in green, nuclei in blue.  Scale bars 50μm. 
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Figure 5.5 
Validation of Collagen and Fibronectin Antibody Specificity:  1μg purified collagen type I or 1μg 
purified fibronectin were blotted in duplicate onto PVDF membrane then incubated with a 
1:1000 dilution of anti-collagen I or anti-fibronectin (Appendix C) and a subsequent 1:10,000 
dilution of rabbit anti-mouse IgG-HRP 
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Figure 5.6 
 Loss of Glycosaminoglycans from the SDL during CHO-induced laminitis. Keratan sulfate (A) 
and chondroitin-6-sulfate (D) were localized, in red, to the dermal lamellae of healthy animals by 
immunofluorescent staining subsequent to 30 minute epitope-revealing digestion.  No staining 
was noted for either antibody in the absence of digestion (B,E).  At OG3 stage disease, there was 
marked loss of both materials in the SDL (C,F). Autofluorescent collagen and keratin visualized in 
green (A-E), basement membrane visualized by staining against laminin in green (F), nuclei 
stained blue.  Scale bars 50µm, representative images shown.     G) Antibody and digestion 
specificity were determined by dot blotting. 5µg of NP-40 extracted material was digested at 
37ºC for 30 minutes with either 0.01 Units of Chondroitinase ABC in a pH 8.0 buffer or 0.01 
Units of Keratanase in a pH 7.4 buffer then blotted onto a PVDF membrane..  The membrane 
was then incubated with a 1:1000 dilution of antibodies against chondroitin-6-sulfate or keratan 
sulfate followed by a 1:10,000 dilution of rabbit anti-mouse IgG-HRP. 
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Figure 5.7 
Complete Loss of All ECM Elements in the SDL in OG3 Laminitis.  Hematoxylin and eosin 
staining of 10μm sections of a representative animal from A) and D) control group, B) and E) OGI 
group, and C) and F) OGIII group.  Scale bars 50μm. 
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CHAPTER 6 
 
DISCUSSION AND FUTURE DIRECTIONS: HOW DO THE MARKERS OF ACUTE CHO-INDUCED 
LAMINAR PATHOLOGY HOLD UP IN OTHER MODELS AND CLINICAL CASES? 
 
6.1 Introduction 
The previous chapters have described in detail several biomolecular hallmarks of the 
pathogenesis of laminitis in a carbohydrate-induced model:  increased expression of ADAMTS-4, 
decreased expression of versican and the canonical wnt signaling pathway, and increased 
expression of MMP-1 and -13.  However, in order to draw conclusions from these data that 
could lead to clinically relevant therapies, it is necessary to determine the expression of these 
markers in other models of disease as well as clinical samples.  To address this, we were granted 
access to the Laminitis Discovery Database tissue repository at the University Of Pennsylvania 
School Of Veterinary Medicine124, and were able to compile sample cohorts from two additional 
induction methods, oligofructose (OF)8 and hyperinsulinemia (HI)125, and from animals 
presenting to the university veterinary hospital with naturally developed disease.  The clinical 
samples were organized into two groups, those animals with supporting limb laminitis (SLL) and 
those with chronic laminitis, who were suspected to have developed laminitis secondary to 
endocrinopathic dysfunction. 
The model of alimentary carbohydrate overload utilized in these studies has been in practice 
for a number of years.  The CHO starch gruel model was developed in 1975 to mimic accident 
ingestion of excess grain6.  More recently, the OF model was developed to mimic laminitis 
associated with overgrazing of lush pasture grass8.  Grazing pasture grasses with high 
concentrations of the non-structural carbohydrate, fructan, have been associated with 
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increased incidence of laminitis, and accidental overgrazing, particularly in the spring and 
summer months, are a leading identifiable “cause” of clinical presentations of laminitis126.   
Endocrinopathic laminitis is a term that encompasses those cases where laminitis develops 
secondary to either equine pituitary pars intermedia dysfunction (PPID), also known as equine 
Cushing’s disease, or equine metabolic syndrome (EMS)127,128.  These conditions are most 
commonly associated with chronic disease.  A unifying feature of these metabolic disorders is 
the development of insulin resistance, resulting in serum hyperinsulinemia.  To model this, 
administration of a constant infusion of insulin through a prolonged euglycemic-
hyperinsulinemic clamp (p-EHC) has been developed125.  A drawback of this model, however, is 
the fact that the p-EHC clamp induces acute laminitis, while endocrinopathic laminitis may 
clinically develop more slowly, over the course of months or years.   
Supporting limb laminitis, while perhaps not as common as the other forms of laminitis, has 
a mortality rate of at least 50%129.  Caused by unequal weight bearing on one limb, frequently 
due to an injury of the contralateral limb, SLL is often characterized by a rapid and severe failure 
of the laminae130.  Indeed, the animals used in this study that were ultimately euthanized for SLL 
were all thoroughbred racehorses that experienced some sort of racetrack breakdown to the 
limb opposite the laminitic hoof.  Presently, the majority of literature concerning SLL consists of 
retrospective studies and gross pathological and biomechanical analyses.  There is little to no 
molecular data concerning the pathogenesis of this type of laminitis.  However, because many 
cases of SLL develop during hospitalization131, these animals are prime candidates for targeted 
therapies to prevent the development of laminitis.   
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6.2 Sample Cohorts 
6.2.1 Hyperinsulinemia Induction 
Healthy Standardbred horses were assigned to either control or treatment groups.  
Horses were fitted with a prolonged euglycemic-hyperinsulinemic clamp (p-EHC) to facilitate 
insulin infusion as described125.  Horses were treated with an initial bolus (45miu/kg body 
weight) of insulin followed by a continuous infusion of insulin (6miu/kg/min) and 50% glucose 
solution.  Sham-treated control animals (n=4) received infusions of a balanced electrolyte 
solution. Horses were euthanized at 24 hours (n=4) or at the onset of OG2 lameness (46±2.31 
hours; n=3).  The hooves of the animals were detached at the metacarpophalangeal joint and 
lamellar tissue dissected.  Blocks of lamellar tissue (5mm x 5mm) were flash frozen in liquid 
nitrogen and maintained at -80°C until use.  Animals were housed at the University of 
Queensland, Brisbane, Queensland, Australia, and the experimental protocol approved by the 
University of Queensland Animal Ethics Committee in compliance with the Animal Welfare Act 
of Queensland (2001). 
6.2.2 Oligofructose Induction 
Healthy Standardbred horses were assigned to either control or treatment groups.  
Animals were dosed with 10g/kg body weight of oligofructose (Raftilose P-95) dissolved in 4L of 
water via nasogastric tube or 4L or water as a control, as described8.  Animals were euthanized 
at 24 hours (n=6 control; n=6 treated).  Blocks of lamellar tissue were dissected from the 
disarticulated right front hoof, as described above, flash frozen in liquid nitrogen and stored at -
80°C until use. This experiment was also performed under the auspices of the University of 
Queensland in accordance with the Animals Welfare Act of Queensland (2001) and approved by 
the University of Queensland Animal Ethics Committee.   
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6.2.3 Clinical Supporting Limb Laminitis Samples 
7 horses were diagnosed with supporting limb laminitis secondary to injury in the 
contralateral limb and subsequently euthanized at the University of Pennsylvania School of 
Veterinary Medicine New Bolton Center124.  The cohort consists of 6 thoroughbreds and 1 
warmblood; 5 mares, 1 gelding, and 1 intact male; ranging in age from 2-10 years old.  After 
owner consent, the affected hoof was disarticulated at the metacarpophalangeal joint, 
sectioned with a band saw, and segments of laminae dissected and flash frozen in liquid 
nitrogen.  Samples were stored at -80°C until use.         
6.2.4 Clinical Chronic Endocrinopathic Laminitis 
7 horses presented with chronic laminitis to the University of Pennsylvania School of 
Veterinary Medicine New Bolton Center and were subsequently euthanized124.  The cohort 
consists of 3 Morgans, 1 Quarter Horse, 1 warmblood, 1 Welsh Pony-Thoroughbred cross, and 1 
miniature horse; 3 mares, 3 geldings, and 1 intact male; ranging in age from 8 to 33 years old.  2 
of the animals had been diagnosed with PPID, while the remainder displayed phenotypic 
indicators of EMS, including obesity.  Estimated duration of “chronic” laminitis ranged from 2 
months to greater than 5 years, according to owner-dictated history.  After owner consent, 
blocks of lamellar tissue were harvested from the front and hind feet, snap frozen in liquid 
nitrogen, and stored at -80°C until use.  In addition, laminar samples from 8 animals euthanized 
for reasons unrelated to lameness or laminitis were harvested using identical protocols and 
utilized as a control cohort for analysis of both the SLL and Chronic samples. 
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6.3 Preliminary Data 
qRT-PCR analyses revealed significant upregulation of ADAMTS-4, MMP-1, and MMP-13 in 
both the acute HI and OF induced samples (Fig 6.1 A and B).  In the HI samples, these genes 
were not significantly upregulated until the 48 hour, or OG2, timepoint, while in the OF samples, 
these genes were elevated at 24 hours.  The increased expression of MMP-13 in the OF 24 hour 
timepoint is also in constrast to the CHO model described in Chapter 5, which did not see 
increased MMP-13 gene expression until OG3 stage disease.  In the clinical samples, only MMP-
13 was significantly elevated in either the Chronic or the SLL animals (Figure 6.1 C and D).  In the 
Chronic cohort (Figure 6.1 C), the highest data point in each of the graphs corresponded to a 
single animal, and, similarly, a single animal was responsible for the highest relative gene 
expression of MMP-1 and -13 in the SLL cohort (Figure 6.1 D).   
 Canonical wnt signaling pathway was significantly down regulated in the HI and Chronic 
groups (Figure 6.2 A and C).  Interestingly, there was no decrease in wnt pathway members in 
the OF model (Figure 6.2 B), and a slight increase in wnt4 gene expression.  While the wnt 
pathway culminating transcription factor, TCF4, was significantly downregulated in SLL laminitis, 
along with the wnt signaling receptor frizzled 4, in SLL laminitis (Figure 6.2 D), neither versican, 
β-catenin, nor wnt4 displayed differential expression between control and laminitic tissues.   
 Expression of the hemidesmosome components, integrins α6 and β4, was likewise 
diminished in the HI and Chronic groups (Figure 6.3 A and C).  The OF samples had a slight but 
significant increase in expression of integrin α6 (Figure 6.3 B), while there was a significant 
decrease in integrin β4 expression in the SLL animals (Figure 6.3 D). 
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6.4 Discussion 
Screening for gene expression of markers we have determined to be hallmarks of laminar 
pathology in a carbohydrate induction model, namely versican and members of the wnt 
signaling pathway, ADAMTS-4, MMPs 1 and 13, and hemidesmosomal integrins, in additional 
models and clinical cases of laminitis provides a great measure of context in which to place our 
previous findings.  This context may give important insight into the pathogenesis of laminitis, 
irrespective of origin.  To that end, the similarity in differential gene expression patterns 
between the CHO, HI, and Chronic samples is striking.  In terms of versican, the wnt signaling 
pathway, and integrin β4, the animals in the HI and Chronic group had identical expression 
patterns to those we have seen in the CHO group.  It is therefore possible that systemic insulin 
levels may play a heretofore unappreciated role in CHO-mediated laminar pathology. 
 Hyperinsulinemia has long been recognized as a risk factor for development of laminitis.  
Increased circulating insulin can be caused by multiple conditions, including obesity, PPID, 
corticosteroid administration, and equine metabolic syndrome (EMS), which is a disease 
characterized by insulin resistance (IR), regional adiposity, and recurring laminitis125,127,128.  The 
mechanism by which insulin may be causing laminitis, however, remains unclear.  Studies have 
been undertaken to discern the role of glucose transport132-134, digital perfusion or 
vasoconstriction135,136, inflammatory cytokines137-140, and various metalloproteases141 in HI 
induced and IR animals, with varying and ultimately inconclusive results.  Addionally, the insulin 
receptor has only recently been localized within the laminae, and it was found to be expressed 
only in endothelial cells of the dermal lamellae142.  However, insulin-like growth factor 1 
receptors (IGF-1R) were localized to the epithelium of the secondary epidermal lamellae as well 
as in cells morphologically consistent with fibroblasts in the dermal lamellae142.  Insulin has been 
demonstrated to have the ability to signal through IGF-1R, particularly in incidences of insulin 
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concentrations above physiologically normal143.  Additionally, gene expression of IGF-1R was 
found to be downregulated in HI laminitis, which is consistent with hyperstimulation of the 
receptor, but without a corresponding increase in serum IGF-1144.   The extent to which IGF-1R 
may have a role in regulating the canonical wnt signaling pathway, however, is unclear.  Insulin 
signaling through the insulin or IGF-1 receptors is known to interface with the wnt signaling 
pathway at the level of the LRP5 and LRP6 co-receptors103,145, and IGF-1 signaling has been 
shown in Xenopus development to suppress wnt signaling between β-catenin and TCF146.   
Additionally, CHO induction has only shown a transitory serum insulin spike, which returned to 
baseline by 6 hours after induction147, so further investigation is warranted to determine the 
specific serum concentration and duration of hyperinsulinemia that may be required to 
stimulate the IGF-1R signaling pathway.  
 Even less clear is the relationship, if any, between metalloprotease expression and 
insulin.  As stated previously, various metalloproteinases have been studied in the development 
of laminitis secondary to HI induction or in IR animals.  MMPs 1, 2, MT1-MMP, and TIMP-3 were 
not found to be differentially regulated during laminitis141.  Additionally, ADAMTS-4 was found 
to not be increased during HI induction, which directly contradicts the data presented above141.  
In that particular study, however, changes in gene expression of ADAMTS-4 may have been 
obscured by the use of primers that did not amplify across an intron, and warrants further 
investigation.  Interestingly, in human chondrocytes, signaling through IGF-1R has been found to 
down regulate expression of MMP-13 at both the gene and protein level, perhaps through 
either NF-κB148 or ERK149 regulation.  It is therefore possible that metalloprotease expression, 
particularly MMP-13, could be a pathophysiological process operating independently yet 
concurrent with the dysregulation of the wnt signaling pathway. This is further indicated by 
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increased gene expression of ADAMTS-4 and MMPs 1 and 13 in both the OF and SLL cohorts, 
independent of differential expression of hemidesmosomal or wnt pathway genes. 
 To that end, the increased expression of MMP-13 across all cohorts provides what could 
be another crucial contextual clue about the development of laminitis.  With the exception of 
the OF group, MMP-13 expression is upregulated later in disease development.  A potential 
common feature of all sample groups at that point in pathogenesis is biomechanical stretch, as 
the hemidesmosome and adherens junctions of the epithelium have ostensibly begun to fail in 
the CHO, HI, and Chronic groups, and the laminae is, by definition, unduly loaded in SLL.  Indeed, 
compression has been shown to induce MMP-13, MMP-2, and MMP-9 gene expression in 
murine costal cartilage explants150.  ADAMTS-5 and MMP-13 gene expression was also found to 
be increased after cyclic tensile strain in sw1353 chondrosarcoma cells151.  Seeing as MMP-13 
expression can also be induced by fibronectin fragments148, it is possible that the mechanical 
strain of late-stage laminitis could trigger a catastrophic positive feedback loop of MMP-13 
expression and activation.  It is also worth noting that, in human pre-osteoblasts, episodes of 
mechanical stretching resulted in down regulation of wnt and β-catenin signaling, which could 
be rescued, at least in terms of cytosolic β-catenin, by lithium chloride pre-treatment152. 
It is interesting to note the differences in gene expression in the OF induction versus the 
CHO.  The oligofructose model was developed to be, in effect, another carbohydrate overload-
based induction, but instead using non-structural carbohydrates similar to those found in 
pasture grass8.   However, these samples were collected according to a strict time course post-
administration of OF and not according to a set lameness score, in an effort to use the samples 
to identify early instigators of disease.  As such, the samples we were able to obtain, collected at 
24 hours, were in fact collected before the clinical onset of lameness, which in another study by 
the same group was found to occur at 28 ± 1.83 hours after induction138.  It is therefore not 
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entirely surprising that ADAMTS-4, which is highly upregulated early in the development of CHO 
laminitis19, is likewise upregulated in an apparently early timepoint in OF induction.  ADAMTS-4 
has also been found to be upregulated at 24 hours by the group who generated the samples; 
however, as stated above, their primers may be suspect.  It is possible that, given samples taken 
at later timepoints or organized by lameness score and not by time, we would be able to see 
more similarity between the carbohydrate induction methods.  The difference between the time 
from induction to onset of lameness between the CHO and OF models may well be due to 
differential fermentation of the carbohydrates by the flora of the hindgut.  Studies in swine have 
linked increased volatile fatty acid (VFA) production and increased insulin production153,154.  As 
horses derive a good portion of their metabolic energy from post-gastric fermentation, it could 
be beneficial to pursue characterizing the VFA profiles generated by each of these 
carbohydrates. 
Taken together, these data aid in hypothesizing a sequence of events in the 
development of carbohydrate or insulin-induced laminitis, illustrated in Figure 6.4.  In the case 
of carbohydrate overload, the hindgut is flooded with excess starch, favoring those bacterial 
species that utilize starch as a substrate.  These conditions lead to an overgrowth of those 
species, to the detriment of other intestinal flora155.  What remains unclear is if glucose itself is 
leaking out of the digestive tract, or if there may be some as yet unidentified toxic bacterial 
byproduct that is being released as a result of the unbalanced bacterial populations.  Based on 
the data from the HI and Chronic tissue cohorts, we hypothesize that carbohydrate overload 
would lead to increased serum insulin. While, as stated above, there has not been clear 
identification of the insulin receptor in laminar tissue, IGF-1R has been localized to the basal 
epithelium of the secondary epidermal lamellae142, and this receptor was downregulated in the 
HI model, suggesting that insulin may be signaling through this receptor144.  IGF-1R signaling has 
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been shown to activate AKT156, which in turn phosphorylates GSK3β88, thus sustaining the 
canonical wnt signaling pathway.  Loss of signaling through this receptor could be a mechanism 
of the loss of canonical wnt signaling seen in the carbohydrate model, which results in loss of β-
catenin protein expression and thus loss of adherens junctions and cell:cell attachment.   
Correlated with the loss of β-catenin is the loss of the hemidesmosome protein integrin β4, as 
demonstrated in Chapter 4.  Carbohydrate overload has also been demonstrated to cause an 
increase in pro-inflammatory cytokines, particularly IL-1β157,158, which is a known inducer of 
ADAMTS-4159.  The upregulation of ADAMTS-4 in the carbohydrate model was shown in Chapter 
3 to lead to increased versican cleavage.  We hypothesize that these two pathways, the 
upregulation of ADAMTS-4 and suppression of canonical wnt signaling, are happening 
concurrently, and ultimately result in the weakening of the epidermal lamellae due to loss of 
cell:cell and cell:basement membrane attachments, as well as the loss of proteoglycan structure 
within the cell.  Due to the biomechanical stressors on the tissue, namely, weight bearing and 
the rotational force of the deep digital flexor tendon, the laminae then begin to experience 
increased stretch as the basal epithelial cells fail.  This results in the upregulation of MMP-13 
and subsequent redistribution of its substrates collagens I and III and fibronectin in the dermal 
lamellae, as demonstrated in Chapter 5.  This timeline is supported by the data presented in 
Chapter 5 showing increases in MMP-13 at the later stages of disease.  Thus, carbohydrate-
induced laminitis is ultimately caused by a combination of loss of the anchoring proteins holding 
the basal epithelium together, activation of two specific metalloproteinases, and biomechanical 
failure. 
In summary, the data presented in this dissertation provide a detailed characterization 
of the molecular pathophysiology of equine laminitis in a carbohydrate induction system, and 
provide some clues as to potential systemic instigators of disease.  Going forward, these data 
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also highlight a critical need for an in vitro cell culture system to answer the lingering questions 
of what exact signaling pathways are involved in laminar pathogenesis and how they interact.  
Retrospective studies undertaken on tissue harvested at specific time points or from clinical 
cases are not sufficient to elucidate these mechanisms.  Studies have been performed in laminar 
epithelia holoclone cultures, however, these culture systems present numerous technical 
difficulties, not limited to the need for a layer of feeder cells, the need for extensive 
supplementation of growth factors, and the technical challenges of obtaining a continual source 
of cells and isolation.  Sorting out the potential interplay between insulin, wnt signaling, and 
mechanical strain in such a system would also aid in providing a timeline of pathogenesis which 
would further aid in designing targeted clinical therapies.   
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6.5 Chapter 6 Figures 
 
 
Figure 6.1 
 Gene Expression of Versican and the Wnt Signaling Pathway: qRT-PCR gene expression 
analysis in samples from A) hyperinsulinemia induced animals, B) oligofructose induced animals, 
C) animals euthanized due to chronic endocrinopathic laminitis, and D) animals euthanized due 
to supporting limb laminitis. 
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Figure 6.2 
 Gene Expression of ADAMTS-4, MMP-1, and MMP-13: qRT-PCR gene expression analysis in 
samples from A) hyperinsulinemia induced animals, B) oligofructose induced animals, C) animals 
euthanized due to chronic endocrinopathic laminitis, and D) animals euthanized due to 
supporting limb laminitis. 
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Figure 6.3 
Gene Expression of Hemidesmosomal Integrins: qRT-PCR gene expression analysis in samples 
from A) hyperinsulinemia induced animals, B) oligofructose induced animals, C) animals 
euthanized due to chronic endocrinopathic laminitis, and D) animals euthanized due to 
supporting limb laminitis. 
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Figure 6.4  
Model of the series of events leading to failure of the digital laminae in carbohydrate and 
insulin induced laminitis 
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APPENDIX A 
 
MATERIALS AND METHODS 
 
Animals, Tissue Collection, and Immunization 
Horses 
Front hoof laminae were collected from 8 healthy horses as previously described53,113.  
Briefly, healthy horses were placed under general anesthesia, their distal right forelimbs 
detached at the metacarpophalangeal joint and the animals euthanized immediately thereafter 
under protocols approved by the IACUC of the University of Missouri College of Veterinary 
Medicine.  Excised hoofs were sectioned using a band saw and segments of lamina 
(approximately 5 mm x 5 mm x 5 mm) spanning from the inner hoof wall to the outer face of the 
distal phalanx were dissected using a sharp scalpel and flash frozen in liquid nitrogen for 
molecular and biochemical analyses. For immunofluorescent microscopy, segments were 
embedded in a commercial preparation of water soluble glycols and resinsa and frozen over dry 
ice (6 of the 8 laminae only).  All segments of laminae were processed or frozen within 5 
minutes of detachment of the distal right forelimb. 
 
Rabbits 
Two female New Zealand White rabbits were immunized with an equine ADAMTS-4-
specific peptide (described below) conjugated to keyhole limpet hemocyanin (KLH) and 
emulsified in an adjuvantb1.  Briefly, each rabbit received 500 µg protein dispersed over 10 sites 
on the back and was boosted three times over the course of 10 weeks with an additional 250 µg 
peptide-KLH emulsified in an adjuvantb2.  The animals were exanguinated 10 days after the last 
immunization, blood collected for serum preparation and serum stored at -20oC until use.  All 
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procedures were carried out under protocols approved by the IACUC of the University of 
Massachusetts.  The peptide, “NTPEDSDPDHFD,” corresponded to amino acids 300-311 of the 
equine ADAMTS-4 sequence and was synthesizedc with an N-terminal cysteine residue to 
facilitate conjugation to the KLH.  The peptide was chosen from an area of ADAMTS-4 predicted 
to be a loop structure in the metalloproteinase domain based on homology to the human 
protein sequence, for which the crystal structure has been solved.    Peptide specific antibody 
was affinity purified from rabbit serum using sepharose beadsd conjugated to the 
“NTPEDSDPDHFD” peptide.  The concentration of purified antibody was determined by 
spectrophotometrye. 
RNA 
RNA was collected from three separate sections of dorsal lamina from each horse using 
an RNA extraction kitf1.  Briefly, flash frozen tissue was pulverized in a pre-chilled (on dry ice) 
slammerg and homogenized in the lysis buffer provided, then passed through the column 
provided and washed accordingly.  The purity and concentration of RNA were determinede and 
extracted RNA was used for cDNA preparation only when the A260:A280 and the A260:A230 
ratios were very close to 2.0.  Integrity of isolated RNA was confirmed by electrophoresis on a 
1.0% agarose gel and staining with a proprietary polynucleotide gel stainh. 
cDNA was synthesized from isolated RNA using a cDNA synthesis kiti. 
PCR 
Relative Quantitative Real Time PCR 
Primer sets were generated against the equine sequence (Appendix B).   GAPDH was 
employed as a housekeeping gene using primers previously described19.  Briefly, RT-qPCR 
reactions were run using a proprietary reaction mixture which contains a high performance 
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reverse transcriptase and reference dyesj according to manufacturer’s instructions and data 
were read with a thermal cyclerf2 as described19.    
Non-Quantitative PCR 
Specific cDNA fragments of four versican isoforms (V0, V1, V2 and V3) were amplified by 
PCR160 using the primers listed in Appendix B. All amplifications were performed for 35 cycles 
following the conditions: 94°C for 2min, 94°C for 30s, 58°C for 30s, 72°C for 1min and 72°C for 
7min using a PCR thermal cyclerk PCR products were visualized after electrophoresis on a 2.0% 
agarose gel by staining with a proprietary polynucleotide gel stainh, and bands were excised, 
purified, and sent for sequence confirmation. 
Protein Extracts 
NP-40 Soluble Material  
~ 0.35g snap frozen segments of dorsal laminae was pulverized in a pre-chilled (on dry 
ice) slammerg and immediately homogenized in 10ml of extraction buffer (50mM Tris pH7.0, 150 
mM NaCl, 5mM ethylenediaminetetraacetic acid, 0.5% NP-40 containing 10μM E64, 1.5μM 
pepstatin A and 1 mM phenylmethanesulfonyl fluoride) on ice. The homogenized sample was 
incubated overnight at 4°C, centrifuged (14,000 g) 15 min in 4°C, supernatant collected and 
protein in the supernatant precipitated by addition of ice cold absolute ethanol to a final 
concentration of 80% v/v. The precipitate was washed with ice cold 80% ethanol twice, dried 
under nitrogen and dissolved in PBS.  Protein concentration was determined by a colorimetric 
assay based on a protein binding dyel1. 
Guanidine Hydrochloride Soluble Material 
～0.35g snap frozen segments of dorsal laminae was pulverized in a pre-chilled slammer 
and homogenized in 5ml of cold extraction buffer (0.1 M PBS, with 5 mM iodoacetic acid, 
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0.1 mM 4-(2-aminoethyl) benzenesulphonyl fluoride, 1% 3-[(cholamidopropyl)-
dimethylammonio]-1-propane-sulfonate, 1 µg/ml pepstatin A, 50 mM sodium acetate, 5 mM 
benzamidine hydrochloride hydrate, 5 mM phenylmethylsulfonyl fluoride, 10 mM N- 
ethylmaleimide, 4 M guanidine hydrochloride, pH7.6) [additionally supplemented with a 
proteinase inhibitor cocktailb3] for 30 sec on ice and extracted overnight (~15 hours) at 4°C. The 
samples were centrifuged at 14,000 g for 30 min at 4°C, a floating layer of insoluble lipids 
removed and the remaining supernatant collected and precipitated overnight with 4 vol. of ice 
cold absolute ethanol containing 5 mM sodium acetate. Precipitated molecules were collected 
by centrifugation at 4°C for 1 hr at 14,000g, dried under nitrogen and the pellet was re-
suspended in buffer and digested with 0.06 Units Streptomyces hyaluronidasem/10µg weight of 
original frozen tissue as described by the manufacturer.  After digestion the supernatant solids 
were precipitated by addition of ice cold absolute ethanol containing 5mM sodium acetate to a 
final concentration of 80% v/v as above, dried and digested with 0.01 Units Chondroitinase 
ABCn/10µg weight of original frozen tissue as per manufacturer’s instructions.  Supernatant 
solids were again precipitated and dried as above and digested with 10 µUnits Keratanase 
IIn/10µg weight of original frozen tissue.  The above digestion protocol allowed solubilization of 
the many molecules that form insoluble macromolecular complexes with hyaluronan and their 
subsequent analysis by SDS-PAGE. 
SDS-PAGE and Western Blotting 
An aliquot (30 μg protein content) of extract was boiled in reducing Laemmli (5 mM 2-
mercaptoethanol) sample bufferl2 for 5min and subjected to SDS-PAGE in a 4% (w/v) 
polyacrylamide stacking gel with a 10% (w/v) polyacrylamide gel as previously described161. 
Proteins were transferred to polyvinylidene fluoride membranes by electroblotting. The 
membrane was blocked with 5% dry milk in PBS with 0.05% tween-20 for 1 hr, washed with PBS 
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with 0.1% tween-20 for 30 min and then incubated with primary antibodies overnight at 4°C 
(Appendix C). After incubation with primary antibodies the membranes were washed twice in 
PBS with 0.1% tween-20 for 30 min and incubated with secondary antibodies conjugated with 
horseradish peroxidase (Appendix C).  Detection was performed using enhanced 
chemiluminescencel3 visualized with a gel imaging and documentation systemo1 and 
quantification was done using associated softwareo2. 
Immunofluorescence 
Frozen sections (10 μm thick) were cut from embeddeda tissues and affixed to treated 
glass slidesp.  Immunofluorescent staining was carried out using methods previously 
described162.  Briefly, slides were blocked with 5% BSA in PBS with 0.001% tween-20 and treated 
with optimal dilutions of primary antibodies, described in Appendix D, for one hour at room 
temperature.  Sections were washed and treated for one hour at room temperature with 
secondary antibodies along with a 1:2000 dilution of DAPI. Actin was visualized by incubating 
tissue sections with a 1:200 dilution of phalloidin-FITCb4 conjugate for one hour at room 
temperature. 
Specificity of staining was established using enzyme digestion and peptide blocking.  Enzymatic 
digestions were carried out for one hour at 37°C as follows: i) for destruction of hyaluronan 
epitopes, sections were treated with 0.01Units of chondroitinase ABCb5 in 20 µl 50mM Tris pH 
6.8 and 60mM sodium acetate with 0.2% BSA.  After digestion, sections were thoroughly 
washed with PBS with 0.001% tween-20, and reacted with antibodies as described above.  ii) For 
peptide competitions, antibodies were incubated overnight with a 10 fold excess of cognate 
peptide or antisense peptide in 1% BSA at 4°C prior to incubation with sections as described 
above.  All slides were imaged using an inverted microscope with apotome grid, UV, blue and 
green excitation light and 20x or 63x objectivesq1. 
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Hematoxylin and Eosin Staining 
10μm sections of unfixed, frozen tissue from a representative control, OGI and OGIII 
animal were dehydrated in ethanol and progressively rehydrated through several changes of 
solution and stained with Gill’s hematoxylin #3 and a 0.5% alcoholic solution of eosin Yb.  Slides 
were imaged on a standard light microscope. 
Quantitation of Tissue Immunofluorescence 
Average fluorescence was calculated using commercially available softwareq2. The basal 
epithelia were traced from crypt to tip of the secondary epidermal lamellae and average 
fluorescence intensity values calculated for the red channel in the enclosed area.  A total of 60 
measurements were taken for each animal, from n=6 control, n=6 OG1, and n=4 OG3 animals.   
Statistics 
Gene and Protein Expression 
Statistical analyses of gene expression and western blot data were performed using 
commercial softwarer.  For RT-qPCR and Western blot results comparisons, the normalized 
values from each horse were analyzed by using the 1-way ANOVA with Dunnett's post test.  In 
cases where data were not distributed normally, a Kruskal-Wallis ANOVA with Dunnett’s post 
test or Mann-Whitney test were used as appropriate.  Pearson product moment correlation co-
efficient analyses with two-tailed 95 % confidence were performed in pairs of expressed 
Western blot bands.  Pearson’s r values can range between -1 and +1 denoting the degree of 
positive or negative correlation between paired data, with a P value of 0.05 being considered 
significant.  The square of Pearson’s r value (r2) denotes (explained variance) ÷ (explained 
variance + unexplained variance).  
Protein Distribution 
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Analysis of immunofluorescence data was performed using a 2-way ANOVA with a 
Duncan’s post test using a commercially available specialized statistical packages. 
 
Product Information 
a. Tissue-Tek O.C.T.; Sakura Finetek USA, Inc., Torrance, CA 
b1. Freund’s adjuvant, complete; b2. Freund’s adjuvant, incomplete; b3. Sigma Fast Protease 
Inhibitor Cocktail; b4. Phalloidin-FITC; b5. Chondroitinase ABC;  Sigma-Aldrich, St. Louis, MO 
c. GenScript USA, Inc., Piscataway, NJ 
d. NHS-Activated Sepharose Fast Flow Beads, GE Healthcare Biosciences, Pittsburgh, PA 
e. NanoDrop 1000; Thermo Scientific, Wilmington, DE. 
f1. Stratagene Absolutely RNA kit; f2. Stratagene MX 3005p; Stratagene, La Jolla, CA.  
g. Biospec Products, Inc., Bartlesville, OK 
h. SYBRSafe DNA Gel Stain; Molecular Probes, Eugene, OR. 
i. Quanta q Script cDNA Synthesis Kit; Quanta BioSciences, Gaithersburg, MD 
j. SYBR Premix Ex Taq; Applied Biosystems, Foster City, CA. 
k. PTC-100PCR System; MJ Research Inc., Waltham, MA 
l1. Bradford Assay; l2 Laemmli Reducing Sample Buffer; l3 E.C.L; Bio Rad Life Sciences, Hercules, 
CA  
m. Calbiochem, EMD, Merck KGaA, Darmstadt, Germany 
n. Seikagaku, Tokyo, Japan. 
o1. G : Box ; o2. Gene Tools ; Syngene, Frederick, MD 
p. Fisher Superfrost Plus ; Fisher Scientific, Fair Lawn, NJ 
q1. Zeiss MOT200 with Zeiss Apotome ; q2. Axiovision version 4.6.3.0 ; Carl Zeiss MicroImaging, 
Inc., Thornwood, NY 
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r. GraphPad Prism Version 5 ; GraphPad Software, San Diego, CA 
s. Proc GLM ; SAS Version 9.2 ; SAS Institute, Cary, N 
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APPENDIX B 
 
PRIMERS UTILIZED FOR RT-PCR AND QRT-PCR 
 
Name Sequence (F - forward 5'; R - reverse 5') GenBank ID 
Amplicon Length 
(bp) 
Efficiency R2 
ADAMTS-4                                
C-terminal 
F-GCGTGGGCTACTATTATGTGCTG-3’                                                     
R-CCACATTGTTGTATCCGTACCT-3’ 
100033914 227 104% 0.976 
ADAMTS-4                               
N-terminal 
F-CAGTATCGAGGGGACCGAACT-3’                                                            
R-GAAATGCTGCCATCTTGTCAT-3’ 
100033914 241 93% 1.000 
Aggrecan 
F-CAACAACAATGCCCAAGACTAC-3’                                                     
R-AGTTCTCAAATTGCAAGGAGTG-3’ 
100033876 110 102% 0.981 
Akt2 
F-AGGACCCCATGGACTACAAGT-3’                                                                
R-CCAGGAGTTTGAGATAGTCGAA-3’ 
100064671 126 95% 0.990 
APC 
F-GACCAGAAGGCAATTGGAATA-3’                                                          
R-GGACTGCAAAAGCTGTCGTAT-3’ 
 100064431 160 99% 0.980 
Axin1 
F-GATCTTCCGGGACAAAGAAG-3’                                                             
R-GCATGGTAGGGTCTTGAATGA-3’ 
 100055241 147 99% 0.980 
β-catenin 
F-CCCTGAACTGACAAAACTGCTA-3’                                                          
R-AATAGCAGACACCATCTGAGGA-3’ 
 100055241 136 98% 0.990 
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CKIα 
F-TTGGGCGTCACTGTAATAAGTT-3’                                                             
R-GCAGTGCCAGTGAGATTTTTAT-3’ 
100060556  118 96% 0.990 
Dsh 
F-ACAACGAGACCAGCACAGAGT-3’                                                                 
R-GTGTTGTCATCCTCGTCTGAGT-3’ 
100147200  205 101% 0.990 
E-Cadherin 
F-CATTGTGTACTCCATCCTCAGC-3’                                                                                                      
R-TGTACTTAAGCCCTCACCTTGA-3’ 
100066844  175 99% 0.990 
FZD4 
F-CTGCTGTTGCTGTTGCTACTC-3’                                                                 
R-GATGAGAGGCGTGAAAGTTGT-3’ 
100050464  189 96% 0.980 
GSK3β 
F-ATCTGCCATCGGGATATTAAAC-3’                                                                                                       
R-ATACGAAACATTCGGTTCTCCT-3’ 
100061033  120 102% 0.970 
Hyaluronan Synthase II 
F-CACAGACAGGCTGAGGACAA-3'                                                                    
R-ACAGGCTTTGGATGATGAGG-3' 
100009708 231 94% 0.930 
Integrin α6 
F-AGTCTGCACATCTTCTTCCTGA-3’                                                                      
R-CGCTCCAATCACTATATCTTGC-3’ 
100064056  122 100% 0.990 
Integrin β4 
F-GATGTGAATGAGTTCCGGAGT-3’                                                                 
R-GTCAGCCTCGTAGTGGAAGG-3’ 
 100051679 183 100% 0.990 
LRP6 
F-GCCAAATGGACTAACTTTGGAT-3’                                                              
R-GTGTCCTCAAATAACGTCAAGG-3’ 
 100063409 159 102% 0.990 
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MMP-1 
F-ATAACTACGATTCGGGGAGAAG-3’                                                                                                          
R-TCTATGGGAAACCTCATAAGCA-3’ 
100033896 153 104% 0.970 
MMP-3 
F-CTTTTGATGGACCTGGAAAAGT-3’                                                               
R-GAGTGATAGAGACCCAGGGAAT-3’ 
100034159 169 91% 0.980 
MMP-13 
F-GTCCCTGATGTGGGTGAATAC-3’                                                                                                                
R-ACATCAGACCAAACTTTGAAGG-3’ 
100009711 152 93% 0.990 
MMP-14 
F-GTTCCTGATAAGCCCAAAAACC-3’                                                              
R-CTTCCTCTCATAGGCAGTGTT-3’ 
14954103 213 104% 1.000 
MMP-15 
F-TTTTCAAAGGTGACCGCTACT-3’                                                               
R-GTCCTCTTGGAAGAAGAAGGTG-3’ 
100062872 158 103% 0.990 
MMP-16 
F-TGGTTACAAAAGTACGGCTACC-3’                      
R-CCTCTTGTCTGGTCAGGTACAC-3’ 
100049862 191 92% 0.980 
PP1 
F-AAAACCTTCACCGACTGCTT-3’                         
R-ATACGCCGAATCTGTTCCAT-3’ 
 100059233 119 97% 0.990 
TCF4 
F-TTCTTTCAGCCAACAGACATTC-3’                       
R-AGTTGCAGACTGGACAGGAAG-3' 
 100049930 128 101% 0.990 
Versican 
F-CCTGCAATTACCATCTCACCTA-3’                          
R-CAGGGAGTTGATTTCATAACGA-3’ 
100065275 122 92% 0.990 
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Versican                                   
V0 Isoform 
F-TGGTGAAGAAACAACCAGTG-3'                                                                   
R-AGTGGTGACTAGATGTTTCC-3' 
100065275 530 N/A N/A 
Versican                                    
V1 Isoform 
F-GCTGAAGAAGAGTGTGAAAA-3'                         
R-AGTGGTGACTAGATGTTTCC-3' 
100065275 520 N/A N/A 
Versican                                   
V2 Isoform 
F-CTCGTGTTCCTCCCACTACC-3'                                                                             
R-TGGGCAAAGTACTTGTAGCA-3' 
100065275 510 N/A N/A 
Versican                                   
V3 Isoform 
F-GCTGAAGAAGAGTGTGAAAA-3'                         
R-TGGGCAAAGTACTTGTAGCA-3' 
100065275 547 N/A N/A 
Versican                                    
G1 Domain 
F-TTATGAAGATGGGTTTGAGCAG-3'                        
R-AGTTTCATGAGGAGAACGGAAT-3' 
100065275 151 101% 0.984 
Versican                                
αGAG Domain 
F-ACACTTCCCATACGGTTTCTCT-3'                        
R-AGGAGAAATAGTCGCTTCAAGG-3' 
100065275 152 108% 1.000 
Versican                               
βGAG Domain 
F-GTTTTCAGCACATCTCTTGAGG-3'                       
R-TTTCTGGTAGCAGATGCTGAAT-3' 
100065275 179 101% 0.999 
Versican                                   
C17 
F-CCTGCAATTACCATCTCACCTA-3'                       
R-CAGGGAGTTGATTTCATAACGA-3' 
100065275 122 92% 0.988 
Vimentin 
F-ACGTTCGTCAGCAGTATGAAA-3’                        
R-GTTAGCAGCCTCAGAGAGGTC-3’ 
100056088  98 97% 0.990 
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Wnt4 
F-AGCTGGAAAAGTGTGGCTGT-3’                               
R-GTCCACAAACGACTGTGAGAAG-3’ 
 100071678 119 103% 0.970 
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APPENDIX C 
 
ANTIBODIES UTILIZED IN WESTERN BLOTTING 
Primary Antibodies 
Epitope Company Dilution 
Rabbit Polyclonal to 
Human ADAMTS-4                             
Catalytic Neoepitope 
FASLSRFVET 
Gift of the Tortorella 
laboratory (Totorella 
et al., 2005) 
1:500 
Mouse Monoclonal [BC-
3] to Human Aggrecan 
ARGSVIL 
AbCam ab3773 1:2,000 
Mouse Monoclonal to β-
Actin 
AbCam ab8226 1:20,000 
Rabbit Polyclonal to 
Human β-Catenin                                       
AA768-781 
AbCam ab6302 1:4,000 
Mouse Monoclonal 
[M168] to Mouse E-
Cadherin                                  
C-terminal region 
AbCam ab76055 1:1,000 
Rabbit Polyclonal to Rat 
GSK3β                                           
AA335-349 
Millipore 07-1413 1:500 
Rabbit Monoclonal 
[EPR2286Y] to Human 
GSK3β serine 9 
phosphorylation 
Millipore 04-1075 1:5,000 
Mouse Monoclonal to 
Human Integrin β4                             
AA1612-1821 
Becton Dickinson 
611232 
1:500 
Rabbit Monoclonal 
[EP1247Y] to MMP-1                       
AA115-140 
AbCam ab52631 1:1,000 
Rabbit Polyclonal to 
MMP-13                                                              
AA250-350 
AbCam ab84594 1:1,000 
Rabbit Polyclonal to 
Versican (V0/V1)                                       
ADAMTS-4 Cleavage 
Neoepitope DPEAAE 
AbCam ab19345 1:2,000 
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Rabbit Polyclonal to 
Versican (V0/V2)                                    
ADAMTS-4 Cleavage 
Neoepitope NIVSFE 
AbCam ab28761 1:2,000 
Rabbit Polyclonal to 
Mouse Versican                                      
AA535-598 (αGAG 
Domain, V0/V2) 
Millipore AB1032 1:1,000 
Rabbit Polyclonal to 
Mouse Versican                                      
AA1360-1439  (βGAG 
Domain, V1) 
Millipore AB1033 1:1,000 
Mouse Monoclonal [V9] 
to Vimentin 
AbCam ab8069 1:1,000 
 
 
Secondary Antibodies 
 
  
Epitope Company Dilution 
Sheep Polyclonal to Mouse IgG(H&L) 
AbCam 
ab6808 
1:10,000 
Sheep Polyclonal to Rabbit IgG (H&L) 
AbCam 
ab6795 
1:10,000 
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APPENDIX D 
 
ANTIBODIES UTILIZED IN IMMUNOFLUORESCENT LOCALIZATION 
Primary Antibodies 
 
 
 
 
 
 
 
 
 
 
 
 
 
Epitope Company Dilution 
Rabbit Polyclonal to Human Aggrecan 
AA89-106 (G2 domain) 
 AbCam ab16320 (no longer 
available) 
1:50 
Rabbit Polyclonal to Human β-Catenin 
AA768-781 
AbCam ab6302 1:100 
Mouse Monoclonal to Chondroitin-6-
Sulfate 
Millipore MAB2035 1:100 
Mouse Monoclonal to Collagen I AbCam ab6308 1:200 
Mouse Monoclonal [M168] to Mouse E-
Cadherin C-Terminal Domain 
AbCam ab76055 1:100 
Rabbit Polyclonal to Fibronectin AbCam ab2413 1:200 
Rabbit Polyclonal to Human Frizzled 4 
AA488-537 
AbCam ab83024 1:100 
Sheep Polyclonal to Hyaluronic Acid  AbCam ab53842 1:250 
Mouse Monoclonal to Human Integrin β4 
AA1612-1821 
Becton Dickinson 611232 1:50 
Mouse Monoclonal to Keratan Sulfate Millipore MAB2022 1:100 
Rabbit Polyclonal to Laminin (Pan-
reactive antibody) 
AbCam ab11575 1:100 
Rabbit Polyclonal to MMP-13 AA250-350 AbCam ab84594 1:100 
Goat Polyclonal to Human Versican (T-
20) 
Santa Cruz 26706 1:20 
Rabbit Polyclonal to Human Wnt 4 AbCam ab91226 1:50 
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Secondary Antibodies 
 
 
 
  
Epitope Company Dilution 
Donkey Polyclonal to Goat IgG - 
Rhodamine RedX Conjugate 
JacksonImmunoResearch           
711-295-147 
1:200 
Donkey Polyclonal to Mouse IgG - 
AlexaFluor 488 Conjugate 
JacksonImmunoResearch            
715-545-150 
1:200 
Donkey Polyclonal to Mouse IgG - 
AlexaFluor 594 Conjugate 
JacksonImmunoResearch           
715-585-150 
1:200 
Rabbit Polyclonal to Sheep IgG - Texas 
Red Conjugate 
AbCam ab6745 1:200 
Donkey Polyclonal to Rabbit IgG - 
AlexaFluor 488 Conjugate 
JacksonImmunoResearch            
711-545-152 
1:200 
Donkey Polyclonal to Rabbit IgG - 
AlexaFluor 594 Conjugate 
JacksonImmunoResearch          
711-585-152 
1:200 
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